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A. ZUSAMMENFASSUNG  
 
Eine geeignete Modellsubstanz für mTHPC (m-tetra (Hydroxy) phenyl Chlorin) als 
Antikrebsmedikament stellt mTHPP oder 5,10,15,20-Tetrakis-(3-hydroxyphenyl) 
Porphyrin dar. Die Substanz mTHPP ist ein hocheffektives Medikament, jedoch weist 
es biopharmazeutische und physiologische Grenzen auf. Aufgrund der geringen 
Wasserlöslichkeit ist die Formulierung von mTHPP eine große Herausforderung.  
Desweiteren hat mTHPP die Tendenz sich in der Zellmembran anzureichern, was zu 
einer erhöhten Gewebetoxizität führt. Durch die Verpackung von mTHPP in 
Nanopartikel können diese Probleme effektiv gelöst werden, jedoch ist die gezielte 
Zerstörung von Krebszellen durch Nanocarrier eine große Schwierigkeit. T-
Lymphozyten sind in der Lage Krebszellen zu identifizieren und zu attackieren. Durch 
vorhandene T-Zell-Rezeptoren auf den Krebszellen erwerben sie die Fähigkeit, 
Krebszellen zu erkennen, anzugreifen und eine „Tumor Autoimmune machinery“ zu 
bilden. Durch die Einschleusung von mTHPP (als mTHPP Nanocomplex) in T-
Lymphozyten wird ein „immune cell based delivery system“ erzeugt. Ein solches 
System kann Krebszellen selektiv auswählen und mTHPP übertragen.  
 
mTHPP bindet durch nicht-kovalente Bindungen an folgenden Polymere: 
Polystyrolsulfonat-Na, Polyvinylpyrrolidone und Chitosan HCl (Protasan®). Diese 
physikalischen Bindungen sind schwach und erleichtern somit die Freisetzung von 
mTHPP. Interessanterweise besitzen diese Nanokomplexe auch eine 
photodynamische Aktivität. Somit stellen sie ideale „Carrier“ für mTHPP zur 
photodynamischen Therapie dar. Polymer-mTHPP Nanokomplexe werden durch 
Elektroporation in Jurkat-Zellen (JZ) eingeschleust, da dies ist eine einfache, kosten 
und zeitsparende Methode ist. Da PNC geladene JZs ein auf Immunzellen 
basierendes Transportsystem bilden, können sie durch eine direkte Verabreichung im 
Blut, Krebszellen identifizieren und dran binden. Der von Krebs betroffene Bereich 
wird mit einer bestimmten Wellenlänge des Lichts angeregt, was zu einer Anregung 
von PNC führt. Dies wiederum führt zu Erzeugung von ROS (Reaktive 
Sauerstoffspezies), die die umgebenen Krebszellen einschließlich der Jurkat-Zellen 
abtötet. 
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PNC wurden durch UV-Spektroskopie charakterisiert um die Bildung von mTHPP-
Polymer-NC zu bestätigen und um die Fluoreszenzeigenschaft zu charakterisieren, da 
dies die Voraussetzung für eine photodynamische Aktivität ist. Die Charakterisierung 
mittels AFM zeigte die Morphologie sowie die PNC Teilchengröße  zwischen 10-80 
nm. Solche kleinen Größen von Nanopartikeln sind geeignet, um  in T-Lymphozyten 
aufgenommen zu werden. Außerdem wurden UV und- Fluoreszenz-Spektroskopie zur 
Quantifizierung von mTHPP genutzt. 
 
So konnte ein Beweis des Konzeptes erbracht werden, die Wasserlöslichkeit von 
mTHPC durch die Komplexbildung mit unterschiedlichen Polymeren zu verbessen. 
Ebenso wurde ein „T-Lymphocyte based delivery system“ für die Phototherapie gegen 
Krebs entwickelt. Die Substanz mTHPP diente als Model für mTHPC und Jurkat-
Zellen wurden als T-Lymphozyten eingesetzt.  
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B. SUMMARY 
mTHPP or 5,10,15,20-Tetrakis (3-hydroxyphenyl) porphyrine is a best suited model 
anticancer drug for mTHPC or m-tetra (hydroxy) phenyl chlorin which is used as a 
second generation photosensitizer in photodynamic therapy (Chatterjee et al, 2008). 
Though, mTHPP is an effective anticancer drug, suffers from biopharmaceutical and 
physiological limitations. The problem pertaining to formulation development arises 
due to very low aqueous solubility (Konan et al, 2002) and tendency of mTHPP to 
accumulate in cell membrane from where it slowly releases and degrades (Ochsner et 
al, 1997). These hurdles can be effectively circumvented by designing nanoparticles 
but targeting cancerous cells through these nanocarriers still remains a major 
challenge. Due to presence of T cell receptors on cancerous cells, they acquire the 
ability to recognise and attack cancerous cells and make a tumor targeting 
autoimmune machinery. This autoimmune mechanism can be exploited to develop an 
immune cell (T cell) based delivery system by loading mTHPP (as nanocomplex) into 
T cells. Such safe homing of mTHPP into T cell is capable of selective delivery and 
targeting cancer cells as well as avoiding numerous side effects associated with 
mTHPP while present in blood.  
 
mTHPP binds with each polymer viz, polystyrene sulphonate Na, polyvinylpyrrolidone 
and Chitosan hydrochloride (Protasan®) through non-covalent bondings. These 
physical bonds are weak therefore facilitates release of drug. Interestingly, these 
nanocomplexes also possess fluorescence, thus acting as an ideal carrier for mTHPP 
for photodynamic therapy. Polymeric nanocomplexes of mTHPP (PNC) are 
internalized into Jurkat cell (JC) by electroporation because this is simple, time saving 
and economic method of intracellular delivery. PNC loaded JCs form an immune cell 
based delivery system which is intended to be administered directly into blood 
following identification and binding with cancer cells. Exposure of cancer affected area 
with suitable wavelength of light leads to excitation of PNC and generation of ROS 
(Reactive oxygen species) which kill surrounding cancer cells including Jurkat cells. 
 
PNC were characterized by UV spectroscopy to confirm formation of mTHPP-polymer 
NC while keeping fluorescence property intact which is prerequisite for photodynamic 
activity. Characterization by AFM revealed morphology and particle size of PNC 
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between 10-80 nm which is smaller enough for effective intracellular delivery. 
Analytical methods by UV and fluorescence spectroscopies were developed for 
quantification of mTHPP. 
 
Thus, a proof of concept was designed pertaining to enhancement of aqueous 
solubility of mTHPC by complexation with different polymers and development of its T 
lymphocyte based delivery system for photoimmunotherapy of cancer using mTHPP 
as a model drug for mTHPC and JCs as model cell for T lymphocytes respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanocomplex T Lymphocytes 
Electroporation 
Nanocomplex loaded T-Lymphocytes                          
(Immune cell based delivery system) 
Cancer Cells (A549) 
Drug 
(Water insoluble) 
(Water soluble) 
 
 
 
Killed Cancer Cells 
Irradiation at 
 457nm 
Polymer 
(Water soluble) 
Fig.1: Graphical abstract; water soluble polymer and mTHPP form photosensitizer-polymer NC. These 
NCs are internalized into T lymphocyte by electroporation. PNC loaded T lymphocytes are incubated with 
A549 lung carcinoma cell line followed by irradiation at 457 nm resulting into killing cancer cells. 
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C. GENERAL INTRODUCTION 
 
1. Photodynamic therapy 
Photodynamic therapy (PDT) is a mode of treatment in which special drugs 
(photosensitizers) are used along with light in presence of oxygen to kill cancer cells. 
Photosensitizers are effective only after activation by certain kinds of light. PDT is also 
called as photoradiation therapy, phototherapy, or photochemotherapy. 
 
1.1. History of PDT 
Role of light for therapeutic purpose is known to human mankind since thousands of 
year (Ackroyd et al, 2001 & Daniell et al, 1991). Skin cancer and various other 
diseases like psoriasis and rickets had been treated by light in ancient Indian, 
Chinese, Greek and Egyptian civilization (Jain et al, 2002 & Lukšienė et al, 2003).  It 
was more than a century ago when cell death was observed due to combination of 
light and some chemical compounds, and today clinical use of PDT is under testing for 
treatment of cancers of head and neck, brain, lung, pancreas, intraperitoneal cavity, 
breast, prostate and skin (Dolmans et al, 2003). A medicine student in Germany 
named Oscar Raab had reported that certain wavelengths of light are lethal to aquatic 
creature infusoria in the presence of acridine (Raab, 1900). At the same time, a 
French neurologist named J. Prime found that oral delivery of Eosin in patients 
suffering from epilepsy have developed dermatitis in areas of body which are easily 
exposed to sun (Prime et al, 1900). In 19th century, Niels Finsen in Denmark had 
found that red light has the potential to treat small pox postules and UV radiation from 
sun can cure cutaneous tuberculosis. He had first time used light for modern day 
phototherapy and achieved Noble Prize (Dolmans et al, 2003). Currently PDT is not 
only used in treatment of cancer but also in the treatment of many other diseases. 
United States Food and Drug Administration (US FDA) has approved PDT as a mode 
of treatment in endobronchial and endo-esophageal cancer (Dougherty, 2002; Oleinik 
& Evans, 1998) as well as premalignancies and early stage malignant lesion of skin 
(actinic keratosis), oral cavity, breast bladder and stomach (Pass, 1993). There are 
many fluorescent drug molecules especially porphyrine derivatives under investigation 
for their photodynamic effect in cancer and other diseases. Recently, the potential 
phototoxicity of Chlorin e6 loaded liposomes was confirmed in Neuro2a and SKOV5 
cell lines along with improvement in the loading efficiency of Chlorin e6 by assembling 
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with cationic lipid 1,2-Dioleoyl-3-trimethylammonium-propane (Mahmoud et al, 2015). 
PEGylated G4.5 PAMAM-Ce6 dendrimers were developed for improved 
photodynamic therapy in a preclinical study of cancer (Bastien et al, 2015). 
 
Several other studies pertaining to photosensitizers in PDT are underway. A brief 
history of evolution of photodynamic therapy since 1900 is presented in Table1. 
 
    Table 1: Brief history of photodynamic therapy (Dolmans et al, 2003) 
1900 Oscar Raab 
showed cytotoxic effect of acridine 
in presence of light against 
infusoria (Paramecium caudatum) 
1901 Niels Finsen 
used light for treatment of 
smallpox and cutaneous 
tuberculosis 
1903 Niels Finsen 
achieved Noble Prize for 
discovery in phototherapy 
1903 H von Tappeiner & 
A Jesionek 
Used eosin topically in presence 
of white light to treat skin cancer 
1907 von Tappeiner& 
A Jodlbauer 
first time used the term 
“photodynamic” 
1911 W Hausmann 
defined photosensitive and 
phototoxicity  haematoporphyrine 
1913 Friedrich Meyer-Betz 
first used porphyrines for 
photodynamic therapy in humans. 
He used haematoporphyrines on 
his hands 
1955 Samuel Schwartz 
synthesized haematoporphyrine 
derivatives (HPD) by acetylation 
and reduction which were twice 
phototoxic than 
haematoporphyrine 
1960 Richard Lipson & Baldes 
described HPD about its 
accumulation and photodetection 
of tumor 
1972 Diamond 
proved HPD induced phototoxicity 
in brain tumor 
1975 Thomas Dougherty 
carried out successful treatment of 
skin cancer 
1975 JF Kelly 
HPD for bladder cancer and twice 
enhanced toxicity of HPD than 
haematoporphyrine 
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1978 Dougherty 
first controlled clinical trials of PDT 
in human 
1999 QLT PhotoTherapeutics first approval of PDT in Canada 
 
 
 
1.2. Mechanism of PDT 
In 1903, Herman Von Tappeiner and A Jesionek have first described the overall 
phenomenon of PDT as “photodynamic action” during treatment of skin tumors with 
topically applied eosin (Fisher, 2001). Today PDT is established in clinical practice for 
treatment of several diseases such as actinic keratosis (Kübler, 2005 & Monfrecola et 
al 2009) and other forms of cancer (Berman et al, 2009; Choudhary et al, 2009; Smits 
et al, 2009), blindness associated with macular degeneration due to aging (Brown et 
al, 2004). The procedure of PDT involves a series of events for which three elements 
are essential viz, photosensitizer (PS), light of suitable wavelength preferably in red 
region (λ ≤ 600 nm) because at this wavelength oxygen is highly permeable to deeply 
seated human tissues. Third requirement is molecular oxygen in singlet state. After 
administration of the photosensitizer, excitation at a wavelength corresponding to the 
absorbance band of the PS in presence of oxygen leads to a multistep photochemical 
events. It results in direct destruction of tumor cell, microvasculature damage in 
parallel to induction of a local inflammatory reaction (Songca et al, 2013).  
 
There are numerous mechanisms possible for the destruction of cells by 
photosensitizer. However, major pathway is type II mechanism (Fig 2 & 3b). The first 
step in type II mechanism starts by absorption of a light by the photosensitizer in the 
singlet ground state to promote it to the short-lived singlet excited state (P
1
) (Fig 1). 
The singlet state decays back to the lowest energy level of excited state via 
intersystem crossing to form a stable triplet excited state (P
3
) where the promoted 
electron in a higher orbit undergoes a spin conversion. The triplet state is sufficiently 
long-lived to take part in chemical reactions and therefore, the photodynamic action 
takes place mostly in the triplet state of PS. Then the reaction between triplet excited 
PS molecule (P3) and triplet state oxygen (
3O) is the key step which leads to formation 
of singlet state oxygen (1O) or reactive oxygen species (ROS). ROS has potential to 
kill tumor cells directly by apoptosis and/or necrosis. 
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Fig.2: Energy level diagram illustrating mechanism of PDT
 
 
The destructive effect exerted by ROS could hamper ion channels e.g. Ca++ channels, 
ion pumps e.g. sarcoplasmic reticulum and sarcolemmal Ca++ pumps, ion exchangers 
e.g. Na+/Ca++  exchanger and Na+/H+ exchanger, and ion co-transporters such as K+-
Cl-, Na+-K+-Cl- co-transporters. These ionic pathways are blocked by oxidation, 
peroxidation of cellular components and inhibition of membrane bound enzymes 
(Kourie et al, 1998).   
 
The major mechanisms of cell death during anti-tumour photodynamic activity involve 
cell damage alongwith vasculature shut-down followed by triggering immune system 
against tumours. Direct cell damage involves destruction of mitochondria and 
cytoplasm through apoptosis, endoplasmic reticulum undergoes autophagy and cell 
membrane is disintegrated by necrosis (Mroz et al, 2011). Vasculatures get depleted 
of oxygen and nutrients through all three processes viz, apoptosis, necrosis and 
Singlet oxygen 
Wavelength ( λ) 
1O2 
3O2 
Energy Fluorescence 
Low energy level 
High energy level 
Triplet oxygen 
Intersystem 
crossing 
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autophagy leading to tumour infraction (Castano et al, 2005). Consequently an 
immune response through stimulation of cytotoxic T cells against tumor cells is 
activated (Plaetzer et al, 2003).   
 
1P    1P*  (short lived) 
1P    1P*  (long lived) 
   3P* + LH    1P
-
 + L
.
+ H+ 
     P
-
 + O2    O2
.
-1P
-
 
 
1P    1P*  (short lived) 
1P    1P*  (long lived) 
   3P* + 3O2    
1P + 1O2
* 
 
Fig.3: type I (a) and type II (b) mechanisms involved in PDT 
 
 
Photodynamic therapy majorly involves Type II mechanism. In this mechanism, 
photosensitizer interacts in excited state with triplet state of molecular oxygen (3O2) to 
generate reactive oxygen species (ROS) and radicals. They can interact with cellular 
components such as nucleic acids, amino acids and unsaturated lipids (Josefsen et al, 
2008). 
 
Other pathway referred as type I mechanism is described in Fig. 3a. PS is excited to 
triplet state like type II mechanism where it directly reacts with biomolecules to bring 
permanent chemical changes within them. This triplet state PS interacts with lipid 
molecules embedded in cell membrane and extract an electron to from cationic lipid 
and PS itself becomes anionic radical (Agostinis et al, 2011). This anionic PS radical 
react with molecular oxygen to produce superoxide radical and singlet state 
photosensitizer. The cationic lipid may also be converted to neutral lipid by accepting 
an electron. This radical lipid molecule interacts with proteins embedded in cell 
membrane.  
 
 
a) 
b) 
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1.3. Application of PDT in patient 
Since inception of PDT in early 1900s, Diamond et al have found potential of 
hematoporphyrine derivative in destruction of tumor cells through sensitization by 
visible light (Diamond et al 1972).  Then first time PDT was demonstrated by 
Dougherty et al in 1975 and it has undergone thorough investigation to enable 
application in patients (Dougherty et al, 1975). Thereafter, promising results were 
obtained during clinical studies of PDT of various malignant tumours (Dougherty et al, 
1978). Studies pertaining to PDT in patients are briefly described here. 
  
A combined approach of PDT using hematoporphyrine derivative (HPD) for 
intravenous injection and 5-aminolevulinic acid (ALA) for topical application were 
tested in 26 patients with 41 skin cancer lesions in head and face. The results of this 
combined PDT were compared against alone PDT using HPD on 28 patients and the 
ALA following CO2 laser ablation on 41 skin cancer patients. The combined PDT has 
shown reduction in dose of HPD as well as period of photosensitive period (Wang et 
al, 2016). In case of long term PDT, 78% cure rate was achieved upon 12 months 
follow up when 20% ALA solution was applied over 14-18 hours and irradiated with 
blue light dose 10J/cm2, 10mW/cm2 (Tschen et al, 2006). A similar treatment protocol 
resulted in 89% cure rate upon 3 months follow up (Piacquadio et al, 2004). In case of 
single treatment pertaining to light-dose ranging investigation, 3 hours application of 
20% ALA cream using red light dose  100 J/cm2, 30mW/cm2 had shown 89% cure rate 
over two months follow up in the low fluence rate group (Ericson et al, 2004). Using 
similar protocol for PDT using red light dose 70mW/cm2, 70J/cm2, two treatments 
resulted in 85% complete response (Sandberg et al, 2006).  
 
1.4.  Advantages of PDT 
Among all methods of anticancer therapy which are practiced today, PDT is the most 
economic and simple mode of treatment. Since last three decades, clinical application 
of PDT has unraveled some advantages over conventional modalities of anticancer 
therapy (Chatterjee et al, 2008).  Chemotherapy requires nurses to get special training 
as well as post treatment course in intensive care. Radiotherapy needs an engineer, 
computerized dosimetry calculation and additional cost due to retreatment using 
isotope. Surgical operations in cancer therapy requires blood transfusion and 
sophisticated operation theatres. Overall, chemotherapy, radiotherapy and surgery are 
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complex and expensive against PDT which is simple and cost effective (Songca et al, 
2013). Further, cure rate associated with PDT is higher such as palliative treatment of 
head and neck cancer (Hopper et al, 2004) and Barrett’s oesphagus (Hur et al, 2003). 
 
1.5.  Nanoparticles in PDT 
Though photodynamic therapy makes use of inert components (light, photosensitizer 
and oxygen), is non- or minimal invasive, offers possibility of repeating treatment 
without cumulative toxicity, excellent cosmetic results, reduced long-term morbidity 
and promise for improved quality of life of patient. Its clinical application as first line 
oncological intervention is yet to be accepted because of some limitations. It is 
challenging to develop a suitable photosensitizer formulation, optimization of dose for 
complete and effective cancer treatment, and hurdles in planning, execution and 
monitoring of responses following treatment (Lucky et al, 2015).  
 
Nanooncology has emerged as an effective therapeutic strategy by exploiting 
anticancer drug-nanoparticles in diagnosis and treatment of cancer. Designing 
nanoparticles of a photosensitizer can circumvent the physiological and 
physicochemical limitations (Konan et al 2002, Bechet et al, 2008).  
 
Nanoparticles in PDT are functionally classified as passive or active (Konan et al, 
2002). An active nanoparticulate delivery system of photosensitizer makes use of  
target tissue receptors or antigens while the passive one are intended for parenteral 
administration for passive targeting such as polymeric nanoparticles, hydrophilic 
polymer–PS conjugates, liposomes, oil-dispersions (Chatterjee et al, 2008).  
 
Passive nanoparticles for PDT are produced either from biodegradable polymers or 
non-polymeric materials such as ceramic and metallic nanoparticles. PLGA (poly-dl-
lactide-co-glycolide) and PLA (Poly-lactide) based nanoparticles have been emerged 
as better alternative than liposomes because of their high entrapment capacity of 
photosensitizers (Thakor et al, 2013). Photosensitizers have poor inherent aqueous 
solubility which produces hurdles in formulation development as well as shows 
physiological limitations due to accumulation in tissues upon parenteral administration 
(Ochsner et al, 1997). Optimization of polymer matrix composition leads to controlled 
degradation and release of photosensitizers at the site of action. In addition, 
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photosensitizer-nanoparticles have shown more phototoxicity than free 
photosensitizers. Size of nanoparticles also plays important role in photosensitizer 
effect; smaller the size of nanoparticles, more the accessibility and internalization into 
cancer cells via endocytosis. Further, smaller size has more surface area to volume 
ratio leading to more exposure of nanoparticles to surrounding environment which 
facilitates faster release of photosensitizers (Konan-Kouakou et al, 2005). 
 
These nanoparticles also allow for active targeting by the incorporation of site-specific 
moieties. Modifying the surface of nanoparticles with polymers like poly (ethylene 
glycol) and poly (ethylene oxide) increases circulation times (McCarthy et al, 2005). 
Polymeric nanoparticles based on PLA and PLGA and second generation 
photosensitizers have been widely explored; p-THPP was entrapped into 
biodegradable nanoparticles based on three polyesters viz, poly (d,l) lactide-co-
glycolide (50:50 PLGA, 75:25 PLGA) and poly (d,l) lactide (PLA) by emulsification-
diffusion evaporation technique which produced < 150 nm particles with drug loading 
of up to 7% (w/w) (Konan et al, 2003a & Konan et al, 2003b). Photodynamic activity of 
these p-THPP loaded polymeric nanoparticles was evaluated on EMT-6 mouse 
mammary tumor cells against free p-THPP (Konan et al, 2003a). Moreover, 
verteporfin loaded PLGA nanoparticles against skin and prostate cancer (Konan-
Kouakou et al, 2005), meso-tetraphenylporpholactol-encapsulated PLGA 
nanoparticles in mouse cancer model (Dougherty et al, 1978) have also been tested. 
Hypericin loaded PLA nanoparticles were investigated in NuTu ovarian cancer cell line 
(Zeisser-Labouebe et al, 2006).  
 
Non-biodegradable nanoparticles play differently in PDT than the biodegradable 
polymeric nanoparticles. As they can’t control release of drug therefore not applied for 
drug delivery purposes but they act as catalyst to produce toxic substances from 
dissolved oxygen. Further, control over size preferably <50 nm is desirable (Chatterjee 
et al, 2008). Photosensitizer loaded non-biodegradable nanoparticles have 
advantages over organic polymeric nanoparticles in terms of stability, control over 
size, shape, porosity and resistance to microbial attack and pH variation as well as 
functionalizing nanoparticles for selective targeting of cancer cells which avoids 
accumulation in normal cells and decreases required photosensitizer concentration for 
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phototherapeutic effect and thereby increases phototherapeutic index of 
photosensitizers (Thakor et al, 2013).  
 
The first ceramic-based nanoparticles for PDT was developed using silica-based 
spherical particles loading antineoplastic drug 2-devinyl-2-(1-hexyloxyethyl) 
pyropheophorbide (HPPH) with 30 nm size. Irradiation with suitable wavelength light 
resulted in efficient generation of singlet oxygen, where the inherent porosity of the 
nanoparticles played important role (Roy et al, 2003). The HPPH-loaded nanoparticles 
caused < 10% viability of HeLa cell upon irradiation at 650 nm. Development of gold 
nanoparticles, whereby the photosensitizer is bound to the surface of the nanoparticle 
(Wieder et al, 2006).   
 
Apart from biodegradable and non-biodegradable nanoparticles, self-lighting 
nanoparticles have also been used in PDT. Self-lighting PDT consists of a 
combination of radiation therapy and PDT. Scintillation or persistent luminescence 
nanoparticles are attached with photosensitizers such as porphyrine compounds. 
Exposure to radiation such as X-rays, scintillation luminescence emits from the 
nanoparticles and activates the photosensitizers to produce singlet oxygen which kill 
cancer cells. However, use of conventional radiation therapy can damage healthy 
tissues therefore lowering the dose of radiation is recommended (Chen et al, 2006).  
 
An approach combining the effect of X-ray and fluorescence emission of 
photosensitizer can reduce the external radiation dose and minimize associated 
phototoxic side effects (Morgana et al, 2009).  The emission spectra of many doped 
nanoparticles such as LaF3:Ce3+, CaF2:Mn2+ and semiconductor nanoparticles like 
ZnO, TiO2 perfectly match with the absorption spectra of some porphyrine derived 
photosensitizers. As an example, excitation of BaFBr:Eu2+:Mn2+ nanoparticles by X-
rays exhibits three peaks in emission bands at 400, 500 and 640nm. This emission 
spectrum matches well with the absorption spectrum of hematoporphyrine. The direct 
application of this approach in biological systems has not yet been reported (Chen et 
al, 2006). Similarly, core-excited nanoparticles therapy (CENT) uses energy like X-ray 
absorbed by core nanoparticles and transfer energy to and heat the shell. The heated 
nanoparticles heat and destroy surrounding cell (Tersigni et al, 2012). 
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Upconverting nanoparticles (UCN) are modified nanometer-sized composites which 
generate higher energy light from lower energy radiation, usually near-infrared (NIR) 
or infrared (IR), through the use of transition metal, lanthanide, or actinide ions doped 
into a solid state host (Boyer et al, 2006). Upconversion nanoparticles can be 
synthesized using several different ionic materials – usually rare earth ions like 
lanthanides and actinides doped in a suitable crystalline matrix (Zijlmans et al, 1999). 
Heer et al, have identified micrometer-sized Er3+/Yb3+ or Tm3/Yb3+ co-doped 
hexagonal NaYF4 as the materials with the highest upconversion efficiencies (Heer et 
al, 2004). 
 
Nanocomplexes of therapeutic substances have also been explored in anti-cancer 
therapy. Nazaran et al, have investigated anticancer potential of MScI (Nazaran et al, 
2014) and BCc1 NCs (Nazaran et al, 2015) designed by nanochelating technology in 
animal models. A combination of p53 gene carrying targeted liposomal nanocomplex 
and Docetaxel attached with anti-transferin receptor antibody were studied in a clinical 
trial Phase 1b for safety and efficacy in advanced solid tumour (Pirollo et al, 2016). 
Photosensitizer entrapped mesoporous silica nanoparticles spread on with folate 
modified lipid bilayer-coated gold nanorods were used to design organic-inorganic 
nanocomplex and tested for synergistic photo-therapy. A combined approach consists 
of photodynamic therapy and magnetic hyperthermia was adopted to effectively kill 
cancer cells using photoresponsive magnetic liposomes. This smart nanoplatform 
consists of hybrid liposomes for an enhanced anticancer effect in which the aqueous 
core was loaded with iron oxide nanoparticles and the lipid bilayer was embedded with 
a photosensitizer (Di Corato et al, 2015).  
 
2. Cancer immunotherapy 
According to International Agency for Research on Cancer (IARC), 14.1 million new 
cancer cases had been diagnosed and 8.2 million resulted in death in 2012 (22000 
deaths per day). Further, deaths due to cancer are expected to rise to 13.1 million by 
2030 (Abastado J-P et al, 2014 & Anderson et al, 2014). Among several modes of 
cancer treatment, cancer immunotherapy (CIT) makes use of certain parts of human 
immune system to fight disease such as cancer. Immune cells such as T lymphocytes, 
B cells, dendritic cells etc. are commonly used for cancer immunotherapy. Harnessing 
the immune system aiming for eliminating tumor is ongoing area of research and 
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promising for a mainstream approach for anticancer therapy (Liu et al, 2014). The 
prestigious journal Science has listed Cancer Immunotherapy as top 10 breakthroughs 
of the Year 2013 (Couzin-Frankel et al, 2013). Thus, it has a huge impact on the lives 
of millions of people in the coming decades. The CIT is carried out in different ways 
either by stimulating own immune system to attack and destroy cancer cells or 
providing immune system with immune components such as man-made immune 
system proteins. Choice of the modes of treatment depends on cancer types. 
Sometime boosting body immune system helps eradication of cancer and other way 
through training immune system against cancer cells appear better strategy. We had 
approached towards harnessing T lymphocytes with polymeric photosensitizer 
nanocomplex to enable them to effectively kill cancer cells. 
 
The immune system is collection of organs, specialized cells and substances which 
help protecting from infection and other disease condition. In case of entry of antigens 
such as bacteria, viruses, threatening pathogens into body, the immune system is 
stimulated and raises alarm to unrecognizable substances. The immune system 
identifies them as foreign bodies and attacks them. Cancer cells are also recognised 
as foreign body by immune system and immune cells such as T lymphocytes, B cells 
attempt to attack and destroy them. Immune cells identify and kill these cancer cells 
as a part of human defence mechanism. In this thesis, the immune system mediated 
by T lymphocyte is exploited for delivery of anticancer-photosensitizing agent to kill 
tumours.  
 
However, the immune system faces tougher time to target cancer cells because of 
their uncontrolled growth. Sometimes similarity of cancer cells with normal cells to 
avoid recognition and a weak anticancer response from immune system is achieved. 
There have been various mechanisms suggested to downregulate the anticancer 
activities mediated by immune cell. Overall, the ability of immune system despite 
recognising cancer cell antigen is limited therefore need arises to identify the cancer 
cells by immune system and strengthen them to fight against cancer cells. 
 
Immune cell based anticancer therapy is an emerging field in oncology. An overview 
of body immune system and its mechanistic understanding in killing cancer cell is 
prerequisite to gain insight into cancer immunotherapy. Cancer immunotherapy or 
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immuno-oncology is a treatment modality which makes use of body’s immune 
system to treat cancer. Thus immune cells targeting cancer cells frame autoimmune 
machinery which is exploited in different ways to serve the purpose of anticancer 
therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: T cells recognize and bind with cancer cells through T cell receptor leading to their destruction 
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In view of the fact that all cancer cells and viruses often produce a protein molecule on 
its surface which is identified by immune cells and it is termed as antigen. This 
molecule is capable of stimulating an immune response upon entry inside the body. 
 
Antigens associated with cancerous cells are bound to class I MHC molecules which 
are proteins, and brought to the surface of the cell by the class I MHC molecule, 
where they can be recognized by the T lymphocytes. If the T cell receptor is specific 
for that antigen, it binds to the complex of the class I MHC molecule and the antigen 
and the T cell destroys the cell (Milstein et al, 2011). 
 
2.1.  Animal studies in cancer immunotherapy 
The breakthrough in cancer immunotherapy came in light from animal studies. Beside, 
different check-point receptors help cancer cells recognizing immune cells signal and 
avoid immune system attack as well as creating an immunosuppressive 
microenvironment. Thus, development of check point receptor inhibitors is exciting 
research in cancer immunotherapy. A combination therapy involving check point 
receptor inhibitors requires consideration over regulatory and budgetary control for 
clinical trial approval. Therefore, pre-clinical study with mouse model is needed for 
accurate determination of optimal therapy with combination immunotherapies (Liu et 
al, 2014). Three important anticancer therapies in clinical trial are showing great 
promises viz, chimeric antigen receptors, anti-CTLA therapy and anti PD1 therapy. 
Research carried out on animals makes critical contribution in these therapeutic 
approaches. 
 
Adoptive T cell therapy using T lymphocytes modified with chimeric antigen receptors 
(CARs) have demonstrated activity in hematologic malignancies in early phase clinical 
trials. Barrett et al have tested the hypothesis in robust leukemia xenograft model mice 
that multiple infusions of RNA CAR into cytotoxic T cells followed by lymphodepleting 
chemotherapy can show antitumor responses (Barrett et al, 2013). Highly reactive 
TCRs with anticancer potential govern the gene therapy against cancer. TCRs 
responsive to melanoma/melanocyte antigens were generated by both immunization 
of transgenic mice and a high throughput screening of human T-lymphocytes. This 
adoptive T cell therapy had shown cancer regression in 36 patients (Johnson et al, 
2009). In a study pertaining to relationship between autoimmunity and improved 
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antitumor immunity, destruction of melanocytes in mice model had shown enhanced 
number of CD8+ T cells. This finding suggested that adaptive immune responses to 
cancer can be triggered from immune-mediated destruction of normal cells (Byrne et 
al, 2011). Monoclonal antibodies specific for CTLA4 (cytotoxic T lymphocyte 4) 
antigen had shown anticancer potential in mouse tumor model and human, however in 
advanced stages of cancer therapeutic effect is not appreciable. These problems were 
addressed in two preclinical studies using mice models viz, TC-1 tumor model and 
mouse memory carcinoma (MMC) model. Anti CTLA4 therapy had shown effect in TC-
1 model but not in MMC model which could be due to lower blockage of CTLA4 
receptors in MMC model (Persson et al, 2011).  PD-1 and its ligand (B7-H1 and B7-
DC) play crucial role in tumor suppression. Blocking both ligands by antibodies was 
investigated in murine pancreatic cancer model. Administration of blocking antibodies 
significantly decreased tumor growth in vivo (Okudaira et al, 2009). 
  
2.2.  Modalities of anticancer immunotherapy  
There are three main types of immunotherapy viz, cellular, antibody and cytokine. All 
immunotherapies provoke the immune system to attack tumor cells by targeting 
antigens on cancer cells. Cellular cancer immunotherapies are designed to provoke 
lymphocyte activation to increase immune response against tumor cells or to enhance 
recognition of tumor cells (Fry et al, 2001). In clinical practice, vaccines are used for 
cell based cancer immunotherapy. A vaccine is a biological preparation which is used 
to acquire active immunity in treatment of a particular disease. Typically it contains an 
antigen or a microorganism which can cause disease but are either half-killed by 
destroying its potential to cause disease or completely killed. They trigger the immune 
system’s recognition ability of any disease causing agent and record it through which 
entry of any such agent is noticed even in later stages. The goal of cancer vaccine is 
to help treating cancer by provoking immune system. 
 
Vaccine can act in anticancer therapy in different ways; either through blocking the 
suppression of immunity induced by tumors or by blocking or removing the cellular 
function through suppression activity, or inducing sensitivity towards apoptosis. 
Cancer cells express suppressive factors which induces immune escape (Baxevanis 
et al, 2009). Vaccines designed against cancer either prevent the occurrence of 
cancer or treat the cancer. Some cancers are caused by viruses; therefore vaccines 
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which help protection against viral infections might also help preventing cancer 
associated with those viruses. Some strains of human papilloma virus (HPV) are 
linked to cervical, anal, throat and other cancers. Anti-HPV vaccine may help 
preventing such types of cancers. In same way, chronic hepatitis B virus (HBV) 
infection has higher risk for liver cancer therefore anti-HBV vaccine may lower the risk 
of liver cancer. These vaccines do not target directly cancer cells but they help 
reducing the cancer. Moreover, these vaccines are useful only for specific types of 
cancer which are caused by viral infection. 
 
Vaccines designed to treat cancer work in different way than cancer-preventing 
vaccines. These vaccines provoke immune system to mount an attack against cancer 
cells, hence they are meant to destroy tumor indirectly. Some cancer treating vaccines 
consist of tumor cells, antigens or parts of cells capable to provoke immune system 
working against cancer cells. Patient’s own cells are also removed to prepare 
vaccines in the lab which are re-injected into the body to enhance immunity against 
cancer cells. Vaccines could also be combined with adjuvants (other cells) which play 
role in further boosting immune response. PROVENGE® (sipuleucel-T) is indicated in 
autologous cellular immunotherapy for the treatment of advanced prostate cancer 
which has acquired resistance to hormone therapy. In order to prepare this vaccine, 
immune cells of patient are removed from blood and exposed to certain chemicals 
which turn them into dendritic cells. They are also exposed to prostatic acid 
phasphatase (PAP) which is a protein, to produce anti prostate cancer immune 
response. Intravenous administration of dendritic cell back into the body helps other 
immune cells to attack prostate cancer. 
 
Regulation of immune system involves an intricate balance of stimulatory and 
inhibitory signals from respective receptors. Some monoclonal antibodies have ability 
to stimulate the immune response by interaction with immune receptor molecule. They 
act either as an antagonist on crucial receptors which suppress immune response or 
as an agonist to activate those receptor which stimulate immune response. An 
antibody is a protein which circulates throughout the body to identify and attach 
specific proteins called antigen. Then, they recruit other parts of immune system to 
destroy antigen-containing cells. 
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Researchers have designed antibodies that specifically target an antigen expressed 
on cancer cells. While the copies of such antibodies engineered in lab are called 
monoclonal antibodies (MCAs). MCAs were first produced by Kohler and Milstein 
through hybridoma technology which has been now modified for therapeutic 
application in cancer. Monoclonal antibodies are hybridoma of mylenoma cells and 
spleen derived antibodies which are monospecific for cancer cells. It is an emerging 
strategy in cancer immunotherapy and initial clinical trials of these MCAs have shown 
promising results (Melero et al, 2007). Different types of MCAs in anticancer therapies 
are naked MCAs, conjugated MCAs, bispecific MCAs and now trispecific MCAs are 
also available on the market. 
 
Naked MCAs are common type of antibodies in cancer therapy. They work by 
themselves without being labelled with drug or radioactive materials. Some MCAs act 
by boosting antitumor immune response by attaching to cancer cells and serve as a 
marker for immune system of body to destroy cancer cells. For example, 
alemtuzumab (Campath®) is indicated in chronic lymphocytic leukemia. It attaches 
with CD52 antigen expressed on lymphocytes including leukemia cells. After binding, 
this antibody recruits immune cells towards cancer cell destruction. In some cases, 
naked MCAs bind and block antigens expressed by cancer cells or nearby cells which 
help growth and proliferation of cancer cells. Transtuzumab (Herceptin®) is such an 
antibody which attaches and blocks HER2 protein that help growing breast and 
stomach cancer cells upon activation. 
  
Conjugated MCAs are combination of MCAs and a chemotherapeutic agent or 
radioactive substance. MCA provides homing to its conjugates and direct them to 
target cancer cells. This conjugate circulates throughout body and reaches to targeted 
cancer antigen where it binds and selectively delivers toxic substances to destroy 
tumor. This selective delivery strategy reduces collateral damage to normal cells. 
Ibritumomab tiuxetan (Zevalin®) is a radiolabeled MCA acts against CD20 antigen 
expressed on cancerous B cells. The antibody delivers radioactive substances 
selectively to cancerous B cells and also applied in non-Hodgkin lymphoma. Such 
type of cancer treatment is also called as radioimmunotherapy. Brentuximab vedotin 
(Adcetris®) is the conjugate of antibody and MMAE which is chemotherapeutic agent. 
It acts against CD30 antigen expressed on lymphocytes. Adcetris® is intended for 
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Hodgkin lymphoma anaplastic large cell lymphoma. Ado-trastuzumab emtansine 
(Kedcyla®) is an antibody attached with DMI chemotherapeutic agent. It targets HER2 
protein highly expressed on breast cancer cells. 
  
Apart from the above mentioned antibodies, monospecific, bispecific and even 
trispecific antibodies are also used in anticancer therapy. Bevacizumab (Avastin®) is a 
monospecific recombinant MCAs for human use which slows down formation of blood 
vasculature by inhibiting angiogenesis. In addition, VEGF induced inhibition of 
dendritic and T cell functions may also be decreased (Melero et al, 2007). It happens 
through blocking the signals of VEGF-A (vascular endothelial factor-A) (Los et al, 
2007). In addition it is used in variety of disease including cancer immunotherapy and 
was first angiogenesis inhibitor available for clinical use in USA (Shih et al, 2006). 
Bispecific antibodies are made up of two parts each from different antibodies means 
two different proteins are attached at the same time. Blinatumomab (Blincyto®) is a 
bispecific CD19-directed CD3 T-cell engager which is intended in treatment of 
Philadelphia chromosome-negative relapsed or refractory Bcell precursor acute 
lymphoblastic leukemia. By binding to both proteins viz, CD19 and CD13, it brings 
cancer and immune cells in proximity leading cancer cells attacked by immune cells. 
Cetuximab (Erbitux®) is an antibody targeting EGFR (Epithelial growth factor receptor) 
which is usually expressed on normal and cancerous skin cells. The side effect of this 
drug is skin rash in some recipients. Though conjugated MCAs are more powerful 
than naked MCAs but conjugated component can cause more side effects. A 
Trispecific antibody (Affimed®, Heidelberg) in multiple myeloma is in pipeline which 
target has yet not been disclosed. 
 
The immune system has ability to distinguish between normal cells and antigens. 
Immune cells possess certain molecules called as check points through which they 
selectively attack foreign bodies. The goal is to activate or deactivate check points to 
bring an immune response. Cancer cells often attempt to avoid these check points to 
bypass their recognition therefore drugs acting on these check points are very 
promising in anticancer therapy. Reports pertaining to check points in animal studies 
have been described. 
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PD1 is a check point proteins present on T lymphocytes while PDL1 is expressed on 
cancer cells. PD1 puts T lymphocytes off from attacking other cells in body, notably 
when PD1 binds with PDL1. This binding provokes T lymphocytes to attack other cell 
and therapy cancer cells evade immune attack. Treatment using MCAs targeting PD1 
or PDL1 boost immune system against tumors and such a therapy has appeared very 
promising. Pembrolizumab (Keytruda®) and Nivolumab (Opdivo®) act on PD1 or PDL1 
targets and are indicated in treating melanoma with a long lasting effect as well as in 
lung, kidney and colorectal cancers. However, collateral damage to normal cells is a 
side effect of this therapeutic approach. CTLA-4 is another check point molecule 
which is expressed on active T cells and deactivates its function. Currently evaluation 
of antibodies against this molecule is under clinical trial (Kirkwood et al, 2008). 
Antibodies acting against CTLA4 inhibit activity of CTLA4 which results in increased 
population of T cells. Thus, depletion of immunosuppressive agents from tumor 
microenvironment is necessary for development of an effective immunity against 
tumor. The microenvironment of tumor contains some immunosuppressive agents 
which decreases the therapeutic effect of vaccine while immunity is induced and also 
during effector phase of response. In order to facilitate the immune response, the 
negative regulator of T cell function can be blocked (Sutmuller et al, 2001). Ipilimumab 
(Yervoy®) is a MCA which binds with CTLA4 and inhibit its functioning. It is indicated in 
melanoma of skin and effect against other cancer type is under investigation. As 
Ipilimumab targets immune cells therefore immune system related serious side effects 
are more in comparison to PD1 or PDL1 targeting drugs. 
  
Non-specific immunotherapies are also practiced in clinical oncology. Here cancer 
cells are not targeted specifically but they trigger immune system and often show 
better anticancer immune response. Non-specific immunotherapeutic agents are used 
either themselves or as an adjuvant to main therapy. This leads to boosting immune 
system to improve immunotherapy using vaccines. Cytokines are mainly used in non-
specific immunotherapy. They are small proteins, peptides or glycoproteins (~5–
20 kDa) which are secreted or remain bound on cell surface. Cytokines include 
interferon, interleukin, chemokines, lymphokines and tumor necrosis factor. Cytokines 
are produced by immune cells such as macrophages, B lymphocytes, T 
lymphocytes and mast cells and other cells, including immune cells  as well 
as endothelial cells, fibroblasts and various stromal cells. They regulate differentiation, 
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growth and activation of immune cells and act as cell signalling molecules to help 
communication between cells in case of immune responses and thereby stimulate the 
mobility of cells towards sites of infection and inflammation. 
 
Examples of cytokines are interferon (IFN) and interleukin (IL) (Dranoff G, 2004 & 
Ananya, 2015). There are different types of cytokines produced in tumor 
microenvironment and play vital role in cancer pathogenesis. They can be crucial in 
inhibiting progress and development of cancer, therefore an improved cancer 
immunotherapy is attributed to cytokine-tumor cell interaction (Dranoff G, 2004). As 
the cytokines present in the microenvironment of cancer cells makes up immunity, 
therefore therapeutic intervention in this surrounding can be strategized for cancer 
immunotherapy. There has been plethora of cytokines investigated in cancer therapy. 
IFN-α and IL-2 are approved by FDA while IL-3, IL-4, IL-6 IL-7, IL-10 are in different 
phases of clinical trial. Denileukin diffitox is a cytotoxic protein derived from 
recombinant DNA and consists of diphtheria toxin fragments A and B and the full-
length IL-2 molecule. Upon administration it inhibits protein synthesis and kill the cells 
in very short time (Mahnke et al, 2007). Cancer immunotherapies through inducing the 
sensitivity of cancer cells to apoptosis have been well studied. Histone deacetylase 
(HDACs) is involved in regulation of cellular functions such as production of 
oncoprotiens viz, PML-RAR or AML1-ETO, tumor suppression by p53 gene. Inhibiting 
HDACs could result in antitumor activity and thereby HDACIs (Histone deacetylase 
inhibitors) can be used in cancer treatment. HDACIs have shown antitumor activity 
through inducing apoptosis of leukemic cells by suppressing expression of oncogenes 
and activating death receptor pathway (TRAIL) which is tumor necrosis factor inducing 
ligand receptor, expressed by tumor cells (Insinga et al, 2005). It is suggested that a 
synergistic anticancer therapy can be achieved by combining apoptosis induction and 
other vaccination and targeted therapy approaches (Baxevanis et al, 2009). 
 
3. Photoimmunotherapy 
Conventional cancer treatment strategies include chemotherapy, radiotherapy, 
surgery, small molecule based therapy and immunotherapy as well as a combination 
of them is practiced. Chemotherapy shows systemic side effect and surgery is 
associated with high rate of recurrence. Treatment using radiation is restricted to 
limited dose. Advancement in search of a safe potent and cost effective cancer 
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treatment led to emergence of immunotherapy and photodynamic therapy. A 
combination of both is promising for a safe, effective and potential mode of treatment. 
Photoimmunotherapy (PIT) is a cancer therapy involve light and body immune cells 
such as antibodies, was first developed at National Cancer Institute, Bethesda, 
Maryland, USA (Mitsunaga et al, 2011). It is a novel type of molecular-targeted cancer 
therapy in which selective destruction of cancer cells is possible without damaging to 
normal tissues. 
 
Conventional PDT makes use of a photosensitizer which can be activated by a non-
ionizing light to kill cancer cells but these photosensitizers are non-specific. Upon 
exposure of photosensitizers to light of suitable wavelength, reactive oxygen 
species (ROS) are produced which rapidly destroy surrounding cells (Park, 2007). 
However, due to non-specificity of these photosensitizers, they are also taken up by 
not-to-be-targeted (normal) cells and results in serious side effects. 
 
PIT treatment is aimed at circumventing these collateral phototoxic effects by creation 
of a targeted-photosensitizer. PIT-delivery system consists of two integral parts: a 
non-targeted photosensitizer and a monoclonal antibody (MCA) which identifies and 
binds with antigen proteins on the surface of cancer cells. Upon administration into 
body, MCAs with photosensitizers recognize and selectively access to cancer cells, 
avoid targeting to normal tissues and then upon exposure to light, they kill the cancer 
cells (Mitsunaga et al, 2017).  
 
The research group at Professor Kobayashi’s lab have coupled a 
phthalocyanine derivative, IRDye 700DX to antibodies targeting human epidermal 
growth factor receptors expressed on tumor cells and photosensitizer dye which was 
activated by near-infrared (NIR) light. IRDye 700DX was chosen for its hydrophilicity 
and strong cytotoxicity induced upon association with the cellular membrane and 
subsequent activation (Mitsunaga et al, 2017).  
 
A variety of cancers, such as breast and pancreatic cancers over-express epidermal 
growth factor receptors (McKeage et al, 2002). This new photosensitizing compound 
utilizing IRDye 700DX NHS Ester was referred to as “mAb-IR700 conjugates”. In vitro 
studies showed that mAb-IR700 killed tumor cells post exposure to the near-infrared 
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light irradiation. A positive correlation between the intensity of excitation light and 
percentage of cell death was observed. Infrared light alone or mAb-IR700 conjugate 
alone could not damage any normal cell. When tumor-xenografted mice were treated 
with combination of mAb-IR700 and near-infrared light, tumor shrinkage was 
observed. With administration of mAB–IR700 conjugate in part followed by repeated 
NIR light exposure, 80% tumor was destroyed to significantly prolong survival of mice 
(Mitsunaga et al, 2011). Current hypothesis reveals that PIT derived cellular toxicity is 
caused by rapid expansion of local water upon the formation of holes in the 
membrane. 
 
Emission of fluorescence light upon activation during PIT using mAb-IR700 conjugate 
was also a required characteristic. Therefore before PIT, a lower dose of mAb-IR700 
can be administered for guidance of excitation light application to targeted tumor 
tissues which minimizes unnecessary light exposure to collateral tissues. 
 
As PIT is an emerging and promising selective cancer therapeutic strategy for 
treatment of mAb-binding cancer with minimal off-targeting. Having clinical feasibility, 
future direction is focused on conjugating a variety of other MCAs to photosensitizers 
such as phthalocyanine. As in PIT antibodies are armed with photosensitizers to get 
photoimmunotherapy, we had used T lymphocytes (having cancer cell receptor) model 
(Jurkat cells) for selective targeting of A549 lung carcinoma cell line creating a delivery 
system for PIT consists of T lymphocytes and polymeric photosensitizers. 
  
4. Photosensitizer 
Photosensitizers are those chemical compounds which undergo a photochemical or 
photophysical alteration on molecular level due to initial absorption of radiation without 
involvement in any chemical reaction (http://goldbook.iupac.org/P04652.html). An 
ideal photosensitizer for photodynamic therapy of cancer is capable to localize 
specifically in neoplastic tissues, accumulates for optimum period in tumor and 
possess short half-life for rapid clearance. When it is activated at desired wavelength, 
shows optimal penetration into tissues, possess high quantum yield to generate 
singlet oxygen and deprived of dark toxicity and should be chemically pure. 
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One of the most important characteristics of photosensitizer in cancer immunotherapy 
is its ability to localise in tumor which is based on the physicochemical properties of a 
photosensitizer. To the best of our knowledge, only animal studies have been done so 
far to determine the tumor:normal tissue ratio which gives insight of extent of tumor 
localisation of a photosensitizer against its distribution into normal tissues. Therefore, 
photosensitizers are classified here based on their tumor localising property (Table.2). 
 
 
Table 2: Classification of photosensitizers 
Photosensitizers Examples 
Hydrophilic compounds: 
They bind to albumin and globulin 
 
Tri and tetrasulphonated derivatives of 
tetraphenylporphine (TPPS3, TPPS4) and 
chloroaluminum phthalocyanine (ClAlPCS3, 
ClAlPCS4) 
 
Amphiphilic compounds: 
They penetrate into outer layer of 
lipoprotien 
- Benzoporphyrine derivative monoacid (BPD) 
- Lutetium texaphyrine (LuTex) 
-  Monoaspartyl chlorin (e6) (MACE) which 
partition between high density lipoportien 
(HDL) and albumin 
 
Hydrophobic compounds: 
They permeate into inner lipid core 
of lipoprotein notably low density 
lipoprotein (LDL) and, also high 
density lipoprotein (HDL) and very 
low density lipoprotein (VLDL). They 
require vehicles like liposomes, 
Tween 80 or cremophor-EL which 
help to solubilize them 
- Unsubstituted phthalocyanines (ZnPC, 
ClAlPC) 
-  Naphthalocyanins (isoBOSINC) 
-  tinetiopurpurin (SnET2) 
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As after administration of photosensitizer for anticancer therapy, tumor targeting out of 
other normal cells is highly desirable therefore tumour localisation of photosensitizer is 
one of the most important characteristics of photosensitizer in cancer immunotherapy. 
 
Only animal studies have been done so far to determine the tumor:normal tissue ratio. 
Tumor localisation ability of a photosensitizer is based on the physicochemical 
properties of a photosensitizer which governs their binding to proteins (albumin, 
globulin), other heavy proteins and lipids of different densities. Thus, photosensitizers, 
based on their tumor localising ability are classified (Castano et al, 2005). 
 
Photosensitizers are also classified based on presence of porphyrine moiety in their 
chemical structure and then further subclassified into first, second and third 
generations.  
 
The first generation photosensitizers are hematoporphyrine, hematoporphyrine 
derivative and Photofrin. Hematoporphyrine was first found to possess very powerful 
photesensitization property and well accumulated in tumor (Meyer-Betz, 1913). 
However, its derivatives had shown better tumor localisation (Figge et al, 1948). Later 
hematoporphyrine derivatives were further purified to isolate Photofrin which is still in 
clinical use (Lipson et al, 1961).  
 
Second generation PS were evolved to overcome limitations associated with first 
generation PS i.e. hematoporphyrine derivatives and Photofrin. Activation at 630nm 
where limited penetration beyond 5mm resulting in no effective treatment of lesions 
and accumulation in cutaneous layer leads to prolong cutaneous toxicity up to 6 
weeks and these PS contains impurities too (Wohrle et al, 1998, Nayak, 2005).  Thus, 
second generation phosensitizers were developed which could successfully 
circumvent above mentioned problems, they are phthalocyanins, naphthalocyanins, 
benzoporphyrins, chlorins, purpurins, texaphyrins, porphycens, pheophorbides, 
bacteriochlorins. These compounds can produce singlet oxygen effectively, have high 
range of absorbance wavelength i.e. 650-850 nm, give a short length photosensitivity 
and are free from impurities as reviewed by Juzeniene et al (Juzeniene et al, 2007). 
Some second generation photosensitizers like Foscan® containing mTHPC (Biolitec 
AG), Visudyne® containing verteporfin (Novartis AG) are used in clinical practice. Upto 
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second generation of photosensitizers, clinical application is evident; however an 
advancement to next generation of photosensitizers can be achieved by intervention 
of novel carriers system or antibodies. When second generation PS are linked to 
nanocarriers, liposomes or antibodies then they are called as third generation 
photosensitizer. Currently these photosensitizers are widely exploited in research 
(Juzeniene et al, 2007). 
 
5. Drug (mTHPP) Profile 
  
5.1.  Description 
mTHPP occurs as dark violet fluffy powder, practically odourless. It is stored in amber 
coloured glass bottle.  
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515 nm     551 nm      591 nm     648 nm 
204 nm 
418 nm 
Fig. 6: UV spectrum of mTHPP in isopropanol (2µg/mL) 
Fig. 5: UV spectrum of mTHPP in EtOH (3µg/mL) 
35 
 
5.2. Spectral properties 
mTHPP shows prominent UV spectrum in solvents such as ethanol and isopropanol. 
Alcoholic solutions viz, ethanolic solution of mTHPP (3µg/mL) and isopropanolic 
solution of mTHPP (2µg/mL) shows peaks at 418nm (Fig.5 & 6). 
 
5.3. Solubility 
mTHPP is practically insoluble in water and freely soluble in ethanol, isopropanol and 
ethyl acetate.  
  
5.4. Chemical structure 
mTHPP is a porphyrine compound. It contains a parent porphine ring which is 
substituted at all four carbons of exocyclic double bond each by the meta carbon of 
phenolic ring. Overall mTHPP contains four double bonds, four pyrrole rings in the 
centre and four benzene rings which enrich mTHPP with plethora of mobile electron 
for excitation. The presence of double bonds and lone pairs of electron make it an 
ideal candidate for complexation with other entities having similar chemical features. 
 
Fig. 7: Chemical structure of mTHPP; Mw: 680 
5.5. Mechanism of action 
 
The mechanism of action of mTHPP is similar to any other photosensitizer used in 
photodynamic therapy to kill cancerous cells. Infact mTHPP is inert in absence of light 
until activated by light to exhibit cytotoxic effect. Upon administration of mTHPP 
compound, it selectively accumulates in the target cells. Then it destroys the lesion 
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with laser light at 425nm or 649nm. Later wavelength is generally used in clinical 
practice for mTHPC. Interestingly, light and mTHPP are individually non-toxic but the 
combination of both elements in the presence of oxygen selectively destroys the target 
tissue (Lukšienė et al, 2003). Excitation of mTHPP followed by emission of fluorescent 
light along with production of radical oxygen species leading to antiproliferative effect 
is previously described under photodynamic therapy. 
  
5.6. Side effects 
Apart from killing cancer cells, mTHPP can kill the surrounding normal cells. 
 
 
6. Polystyrene sulphonate (PSS) 
Polystyrene sulfonates are polymers derived from polystyrene containing sulfonic acid 
or sulfonate functional groups. The crosslinked material (called a resin) does not 
dissolve in water and typically appears amber colored but the linear polymer which is 
Ca++ and Na+ salts appear white when very pure and is water-soluble. PSS is insoluble 
in organic solvent like ethanol, ethyl acetate. Salts are used as Ca++ and Na+ 
replenisher upon oral delivery (Dardel et al, 2008).  
 
 
Fig. 8: Chemical structure of polystyrene sulphonate sodium 
These polymers are classified as polysalts and ionomers. The fluorescein tagged PSS 
appears dark yellow fluppy powder, practically odourless.  
 
7. Kollidone® (Polyvinyl pyrrolidone/PVP) 
Kollidone® is chemically Polyvinylpyrrolidone. It is a widely used synthetic excipient in 
pharmaceutical and cosmetic industries. There are four different grades of Kollidone®; 
Soluble Kollidone® (povidone) grades, Insoluble Kollidone® (crospovidone) grades, 
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Kollidone® VA64 grades (copovidone) and Kollidone® SR. Intially W. Reppe at BASF 
(the chemical company), had synthesized soluble Kollidone® (povidone) grades which 
was later on followed by synthesis of other insoluble grades and now has become one 
of the most important pharmaceutical and cosmetic excipient.  
 
As a matter of fact all grades are based on water soluble polyvinylpyrrolidone which 
are further chemically modified to synthesize other grades of Kollidone®. A physical 
cross linking process of vinylpyrrolidone results in insoluble grades of Kollidone® while 
water soluble co-polymerisation of vinylpyrrolidone and vinyl acetate forms Kollidone® 
VA 64 or copovidone. A mixture of polyvinyl acetate and povidone (8:2) is available on 
the market with the tradename of Kollidone®SR for sustained release purposes.  
 
Fig. 9: Chemical structure of Polyvinylpyrrolidone 
Considering the design of mTHPP nanaocomplex using PVP, we had used water 
soluble Kollidone® grades or povidone. The soluble PVP is obtained by radical 
polymerization of vinylpyrrolidone in water or 2-propanaol. There are six grades of 
soluble Kollidone®viz, 12PF, 17FP, 25, 30 and 90F among which first two are 
endotoxin free. Kollidon® 25 was used in the PhD project for synthesis of PVP-mTHPP 
nanocomplex.   
 
7.1.  Kollidone® 25 
Kollidone® 25 or PVP or polyvidone or povidone, is a water-soluble polymer consists 
of monomer N-vinylpyrrolidone. It is amorphous and appears as white free flowing 
powder, tasteless and has faint ammonia like odour. PVP is more than 10% soluble in 
water, methanol, ethanol, diethylene glycol, propylene glycol, glycerol and less than 
1% soluble in ethyl acetate, diethyl ether and liquid paraffin. It is officially included in 
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Pharmacopoeias of Europe, USA and Japan. All pharmacopoeias have described K 
value for each soluble Kollidone® based on the relative viscosity in water and 
molecular weight of PVP.  The K value of Kollidone® 25 is 22.5 to 27.0. It is non-toxic, 
biodegradable and a good complexing agent and used as a soluble carrier for proteins 
(von Specht et al, 1973). Its good complexation ability is attributed to the presence of 
lone pair of electrons on N and O atoms of lactam unit and active binding sites for 
hydrogen donors (Rothschild et al, 1972). PVP is used as a plasma volume expander 
(Motiff et al, 1975) and due to its property of binding with certain drugs, dyes and 
toxins acts as a carrier to eliminate toxins and retard drugs.  
 
PVP has also been explored for designing drug delivery and medical devices. Taxol is 
a novel antitumor alkaloid possessing anti tumor activity against several types of 
tumours. Using PVP, a novel polymer based Taxol nanoparticulate formulation was 
prepared by reverse microemulsion method. These 50-60 nm particles were evaluated 
in B16F10 murine melanoma transplanted in C57B1/6 mice (Sharma et al, 1996). 
Water-soluble macromolecules such as FITC–dextran (FITC–Dx)-encapsulating 
injectable hydrogel polymeric nanoparticles of polyvinylpyrrolidone cross-linked 
with N,N′-methylene bis-acrylamide were prepared as a reverse micellar droplets. This 
revealed PVP as a potential carrier for hydrophilic drug too (Bharali et al, 2003). 
 
7.2. Polyvinylpyrrolidone as a complexing agent 
Polyvinylpyrrolidone holds an excellent candidature of complexing agent and has been 
widely used because of its complexation attribute in designing biosensors and drug 
delivery purposes. Povidone-Iodine is a commonly known complex of antiseptic iodine 
and PVP. This complex reduces toxicity and obliterating the staining property of iodine 
while keeping up antiseptic activity of iodine intact (USP). Biosensors for detection of 
glucose level in diabetes make use of PVP alongwith graphene, nickel and Chitosan 
(Saroj et al, 2013).  
 
8. Chitosan hydrochloride (Protasan®) 
Chitosan is a linear polysaccharide composed of randomly distributed β-(1-4)-
linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated 
unit). It is made by treating shrimp and other crustacean shells with the alkali sodium 
hydroxide. Chitosan is available in various grades for biomedical applications. 
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Protasan® is a brand of Chitosan hydrochloride which is available in different 
molecular weights.  PROTASAN® is a Chitosan in which > 90 percent of the acetyl 
groups are removed. The polymer with cationic head is a highly purified and well-
characterized water-soluble chloride salt. The functional properties are described by 
the molecular weight and the degree of deacetylation. The average molecular weight 
for PROTASAN® is 100,000 g/mol range (measured as a Chitosan hydrochloride). The 
ultra-low levels of endotoxins and proteins allow for a big variety of in vitro and in vivo 
applications. 
  
Chitosan has a number of commercial and biomedical applications. A novel drug 
delivery systems based on Chitosan nanoparticles containing aminolevulinic acid 
derivatives such as prodrug (5-ALA and its ester derivative 8-ALA) were developed, 
characterized and evaluated for the in vitro cytotoxic activity. Further the synergistic 
effect of combined classical PDT and electrochemotherapy, were investigated in 
treatment of cutaneous neoplasms (Ferreira et al, 2013). Tamoxifen is a broad 
spectrum drug with limited clinical application. The smart pH-responsive drug delivery 
system based on Chitosan nanoparticles for controlled release Tamoxifen was 
developed. Tamoxifen loading into Chitosan nanoparticles and its release at pH 7.4 
(tumor microenvironment pH) has shown improved anticancer activity in human breast 
cancer MCF-7 cells (Vivek et al, 2013).  
 
 
 
 
 
Fig. 10: Chemical structure of Protasan
®
 (Chitosan hydrochloride) 
 
 
 
 
 
 
 
 
 
 
NH2.HCl 
NH2.HCl 
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D.  INTRODUCTION 
Last few decades have witnessed a phenomenal advancement in science and 
technology which led nanotechnology to emerge as a versatile field in delivering 
plethora of drug molecules for therapeutic purpose. Nanoparticulate delivery systems 
have been widely investigated in designing treatment strategies and circumventing 
associated toxicities and side effects of drug molecules. Different treatment strategies 
for major diseases like cancer, tuberculosis, diabetes etc. have been extensively 
improved by designing nanoparticles of drug molecules and toxicity associated with 
drug molecules were reduced. Wu et al, have designed PLGA/HPMCP nanoparticles 
for oral delivery of insulin and investigated its antidiabetic potential (Wu et al 2012). 
Kumar and co-workers have reduced the toxicity issues associated with amphotericin 
B (Italia et al, 2009) and cyclosporin A (Italia et al, 2007) in parallel to enhancement in 
oral bioavailability and solving biopharmaceutical hurdles arise from high molecular 
weight and low aqueous solubility. Schneider and co-workers have formulated 
nanoparticles of several drug molecules for improved therapy including cancer. 
Recently, tetranidine loaded poly-dl-lactide-co-glycolide (PLGA) nanoparticles (Schi et 
al, 2015), idarubicin encapsulated PLGA and maleate polyester-polymer 
nanocomplexes (Blaudszun et al, 2015) were designed and their anticancer potential 
was investigated against cancer cell lines. A drug multilayer based nanocarrier 
consists of Gold nanoparticle core multiple times layered by the polymeric 
nanocomplex of the model photosensitizer drug 5,10,15,20-Tetrakis (3-hydroxyphenyl)  
porphyrine or mTHPP for photodynamic therapy of cancer (Reum et al, 2010). 
 
All chemotherapies of cancer practiced nowadays are associated with severe side 
effects; therefore amount of drug used in anticancer treatment must be minimised. 
However, this leads to a non effective therapy due to sub-therapeutic dose of drug 
reaching to tumor tissues. Moreover, selective accessibility of anticancer drug to 
cancer cells is also challenging. This limitation of existing cancer chemotherapy has 
suggested the growing need of an effective delivery system which can be fulfilled 
through interdisciplinary research of engineering, pharmaceutical science and 
molecular biology. Advent of nanoparticles in advanced drug delivery is very promising 
to overcome the limitations of existing cancer chemotherapy (Bechet et al, 2008). 
Different nanocarriers such as polymeric nanoparticles, liposomes and micelles have 
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been introduced to modulate the pharmacokinetics of conventional chemotherapeutics 
(Khan et al, 2010). These nanocarriers are associated with many advantages such as 
they are internalized into cells without recognition from efflux mechanism e.g. p-
glycoprotein which enhances intracellular concentration of drugs (Cho et al, 2008). 
One of the main advantages is that it facilitates transport of hydrophobic drugs in the 
body without aggregation and loss of drug activity. When coated with poly (ethylene 
glycol), blood circulation time increases leading to enhanced tumor tissues 
accumulation by Enhanced permeation and retention (EPR) effect (Matsumura and 
Maeda, 1986; Duncan et al 2003). Further, the immunogenicity is minimized and 
resistant to microbial attack is acquired (Bechet et al 2008 & Chatterjee et al 2008).  
 
Among several nanocarriers in anticancer therapy, Doxil® is clinically approved as well 
as PEGylated liposome based formulation (Gabizon et al, 2001). These PEG-lipids 
make hydrophilic corona in micelles which allows micellar based delivery system for 
longer time circulation in blood (Blanco et al, 2009). While the PEG moiety helps 
accumulation of drug at tumor site, a stearic hindrance between cancer cells and 
nanocarrier appears which reduces tumor cell uptake (Gabizon, 2001 & Hatakeyama 
et al, 2007). Mixed micelles of monoclonal antibody (MCA) 2C5-DSPE-polyethylene 
glycol and polyhistidine-polyethylene glycol incorporating paclitaxal were synthesised 
for an improved anticancer efficacy by enhancing specific internalization into tumor 
cells through endocytosis mediated by antibody and drug release triggered by lower 
pH of endosome (Wu et al, 2013). 
 
During angiogenesis, the defective pores are formed on vasculatures innervating 
cancer cells. Small size nanaocarriers (≤100nm) extravagate through these pores from 
blood circulation to the tumor cells (Maeda et al, 2000). DaunoXome is a liposomal 
formulation of Daunorubicin which is a cytostatic agent in treatment of cancer- Kaposi 
sarcoma (Torchilin, 2007), or ovarian and recurrent breast cancer (Wang et al, 2008). 
Some other liposomal-based formulations are CPX-1 and LE-SN38 which contains a 
topoisomerase I inhibitor in colorectal cancer or colon cancer therapy. At present, they 
are in Phase-II clinical trials (Kraut et al, 2005; Batist et al, 2009). Polymers such as 
poly-dl-lactide-co-glycolide (PLGA) which is approved by US FDA, has also been 
widely explored due to its biocompatibility and biodegradability. Vincristin and 
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verapamil co-loaded PLGA nanoaprticles were synthesised to get enhanced efficacy 
and reduced toxicity against multidrug resistant breast cancer (Chen et al, 2014). 
 
Though nanocarrier based drug delivery system in cancer therapy appear promising, it 
faces several obstacles in effective delivery of drug to tumor tissues such as transfer 
of drug from its ‘nanohoming’ to cancerous cells at tumor site is very difficult. It might 
be possible that the lethal dose of drug does not reach to the tumor tissues resulting in 
a non-effective killing of cancer cells. In addition, these nanocarriers are prone to 
opsonisation during circulation and thereby less amount of delivery system reaches to 
cancer cells within tumor site (Gabizon et al, 2001; Photos et al., 2003).  
 
These limitations of nanaocarriers for anticancer therapy can be very well 
circumvented by designing Immune cell based delivery systems which are one of the 
advanced drug-delivery systems used in cancer immunotherpay. In brief they are 
made by first internalizing anticancer macromolecules or nanomaterials into immune 
cells and then to target cancer cells.  
 
In addition, 5,10,15,20-Tetrakis (3-hydroxyphenyl) porphyrine or mTHPP which is the 
model drug of anticancer agent 5,10,15,20-Tetrakis (3-hydroxyphenyl) chlorin 
(mTHPC) is suffering from physiological and biopharmaceutical problems due to 
accumulation in tissue after delivery and poor solubility in water during formulation 
development. 
  
Considering the problems associated with mTHPP, adeptness of autoimmune 
machinery in attacking cancer cells, we had proposed to design mTHPP nanocomplex 
loaded T lymphocyte for an effective and safe immune cell based delivery system for 
cancer immunotherapy. Precisely, complexation of mTHPP with water soluble 
polymers viz, polystyrene sulphonate, polyvinyl pyrrolidone and chitosan produces 
water soluble mTHPP-polymer nanocomplex which is internalised into Jurkat cells 
(model T cells) to develop immune cell based delivery system. Upon injecting this 
immune cell based delivery system into blood; they identify and target cancer cells.  
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E.  MATERIALS AND EQUIPMENT 
 
1.  Materials 
Table 3: List of materials or chemicals used in the experiments 
Materials/Chemicals Specifications/Grade Supplier 
mTHPP - Sigma Aldrich 
PSS Na 4300 Da Sigma Aldrich 
PVP 31000 Da, Kollidone® 125; BASF 
Chitosan HCl 100,000 Da, Protasan®  Sigma Aldrich 
Purified water MilliQ Stibel Eltron Comfort 
Ethanol (<99% pure) HPLC grade Sigma Aldrich 
Isopropanol Spectrophotometric grade Sigma Aldrich 
Jurkat cells Human lukaemic blood T-lymphocytes Sigma Aldrich 
A549 cells Human lung carcinoma cells Sigma Aldrich 
RPMI medium - Sigma Aldrich 
EBSS - Sigma Aldrich 
DMEM - Sigma Aldrich 
Trypsin EDTA - Sigma Aldrich 
Water Puriefied water Inhouse facility 
FluorSaveTM                    - Merck Millipore 
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2. Equipment 
         Table 4: List of equipment used in the experiments 
Equipment Supplier 
Centrifuge Thermoscientific® 
Vortex Lab Dancer® 
Clean bench  Labguard class II biological safety      
cabinet 
Filter 0.22µm  Merk Millipore® 
Incubator-cum-shaker IKA® KS 4000 
Electroporator BIORAD Gene PulsorTM 
Electroporation cuvette 0.4cm, Sigma Aldrich® 
Micropipette Metler Toledo® 
AFM JPK® 
Light microscope Nikon TMS® 
Water purifier Stibel Eltron Comfort® 
UV spectrophotometer Multiscan Go, Thermosceintific® 
Fluorescence 
spectrophotometer 
Fluo Star Optima® 
(Optima control software) 
Atomic force microscope JPK® 
Confocal laser scanning 
microscope 
- DMI6000 Leica® TCS SP5 
- LSM880 Zeiss® 
Autoclave Stansautoclave Systec® VX-95 
Weighing balance PioneerTM OHAUS 
Magnetic rotor-cum-heater CAT® MCS66 
45 
 
Chemical structure drawing 
software 
Chem Bio Draw Ultra 4.0 
LED (Laser emitting diode) Lumundus Eisenach® GmbH 
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F. EXPERIMENTAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: Experimental design of PhD work 
Haemocompatibility studies of T-cell 
based delivery system 
Anticancer activity testing of T-cell based 
delivery system 
Dark cytotoxicity assay of Polymer-
mTHPP nanocomplex 
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mTHPP nanocomplex by electroporation 
(T-cell based delivery system) 
 
Characterization of T-cell based delivery 
system 
Morphology of T-cell based 
delivery system 
(CLSM) 
 
Intra-T-cellular-mTHPP 
quantification 
 Fluorescence spectroscopy)  
Analytical method development 
(UV and Fluorescence) 
Synthesis of Polymer-mTHPP 
nanocomplexes 
Characterization of Polymer-mTHPP 
nanocomplexes 
Complexation 
efficiency  
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Zeta potential, size 
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1. Analytical method development by UV and fluorescence spectroscopies 
UV-analytical method for mTHPP was developed in ethanol and isopropanol for 
quantification of mTHPP and determination of complexation efficiency (CE) of each 
nanocomplex. An analytical method by fluorescence spectroscopy was also 
developed for quantification of mTHPP present intracellular as a complex with 
polymer.  
 
1.1. UV spectroscopy of mTHPP in ethanol and isopropanol (IPA) 
mTHPP was weighed and dissolved in ethanol and isopropanol to produce 500µg/mL 
alcoholic (EtOH and IPA)  solutions of mTHPP. First, the blank (ethanol and IPA) was 
scanned between 200-800nm range for the baseline and then 3µg/mL ethanolic and 
2µg/mL isopropanolic solutions of mTHPP were scanned to get the UV spectrums of 
mTHPP (Fig.5 & 6). Then, the absorbance of all solutions in calibration curve was 
measured at λmax=418nm. Both alcoholic solutions of mTHPP (500µg/mL) were 
serially diluted (1:10) to produce a range of concentration between 500 to 0.05 µg/mL 
and curves (Extinction v/s Concentration) (Fig.11) was made. In view of Beer 
lambert’s law, a serial dilution (1:1) was made between 50 to 0.20µg/mL and a linear 
curve was extracted from absorbance values ≤ 1.4.  
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Fig.12: Calibration curve of mTHPP (500 to 0.05 µg/mL) 
a) mTHPP in EtOH (L)    &       b) mTHPP in IPA (R) 
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Finally, a standard curve (Extinction v/s Concentration) was made between 
concentration range 1.56 to 0.20µg/mL (Fig.13). This calibration curve shows a linear 
relationship between absorbance and concentration (R2 = 0.9993 for mTHPP in EtOH 
and R2 = 0.9998 for mTHPP in IPA).  
 
1.2. Fluorescence spectroscopy of mTHPP in ethanol and isopropanol 
As mTHPP is well extractable from its nanocomplexes in ethanol (mTHPP-PSS and 
mTHPP-PVP NCs) and in isopropanol (mTHPP-Chitosan), a calibration curve in 
ethanol and isopropanol (with 2% TritonX 100) was made by fluorescence 
spectroscopy.  
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Fig.13: UV-calibration curve of mTHPP in EtOH (L) and mTHPP in IPA (R)  
Fig.14: Fluorescence spectrums of mTHPP upon excitation at λexc = 405 nm 
 (L) EtOH (λem = 656)   and          (R) in IPA (λem = 653)  
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During extraction of mTHPP from intracellular NC, Triton X100 is used as cell lysing 
agent; therefore calibration curve was made in presence of 2% Triton X100.  First the 
fluorescence spectrums of mTHPP in ethanol and isopropanol were obtained. 
  
mTHPP was weighed and individually dissolved in pure ethanol and pure isopropanol 
to produce 250µg/mL solution. These solutions were serially diluted as 1:1 in light 
protected 96 well plates. Fluorescence emission was measured at λexc= 415 nm and at 
λem= 670 nm against blank ethanol and isopropanol. A standard curve was made 
between 7.81-250ng/mL (mTHPP in EtOH) with R2=0.9994 and 15.63-250ng/mL 
(mTHPP in IPA) with R2 = 0.9989 (Fig.15).   
 
   
 
 
2. 2. Development of mTHPP- Polymer loaded Jurkat cell based delivery system 
 
2.1. Synthesis of mTHPP-Polymer NCs 
Three polymers viz, Polystyrene sulphonate-Na (4.3kDa, Sigma Aldrich), 
Polyvinylpyrrolidone/Kollidone®125 (31kDa, BASF) and Chitosan-HCl/Protasan® 
(100kDa, Sigma Aldrich) were used to synthesize the PNCs with mTHPP (680Da, 
Sigma Aldrich). Each polymer (15mg) was weighed and individually dissolved in 4mL 
purified MiliQ water (Stibel Eltron Comfort) and mTHPP (10mg) was weighed and 
dissolved in 4mL ethanol (>99% pure, Sigma Aldrich) for each aqueous polymeric 
solution. Aqueous solution of polymer was added to the ethanolic solution of mTHPP 
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Fig.15: Fluorescence calibration curve of mTHPP in EtOH (L) and mTHPP in IPA (R)  
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to get a hydroalcoholic mixture. It was thoroughly mixed by vortex for 2 minutes to 
ensure complete interaction between polymer and mTHPP. The mixture was then kept 
at -80ºC over 30 minutes for prefreezing. The frozen hydroalcoholic mixture was 
freeze dried over 24hr. The samples in 50mL tube were completely covered by 
aluminium foil to avoid exposure to light and small pores were made on the top to 
allow escape of sublimed ethanol and water during freeze drying. Sufficient quantity of 
water was added to freeze dried samples and stirred thoroughly on vortex 
(Labdancer®) followed by centrifugation (Thermoscientific®) over 3 minutes at 2500rcf. 
Supernatant was taken out by micropipette and filtered through polycarbonate filter 
(0.22μm pores, Merk Sigma Aldrich®) under vacuum. Water was again added in 50mL 
tube, followed by vortex, centrifugation and filtration; the procedure was repeated 
thrice. The filtration resulted in separation of aqueous solution of PNC as a filtrate and 
free mTHPP as a residue on the filter. More water was added thoroughly on filter to 
dissolve out any PNC adsorbed on mTHPP or filter. During the experiment care was 
taken to avoid exposure to sunlight by covering with aluminium foil or using light 
resistant apparatus. PNCs prepared by above method were taken for quantification of 
complexed mTHPP by UV (Multiscan GO, Thermoscientific®) analytical method. 
 
2.2. Preparation of PNC loaded JC based delivery system 
Sub-toxic concentrations of mTHPP-PSS NC, mTHPP-PVP NC and mTHPP-Chitosan 
NC for JC were determined by MTT assay. Jurkat Cell (Capricon Scientific®) 
suspensions (20x103, 40x103 and 80x103 cells) in 250μL RPMI medium (Capricon 
Scientific®) and 250μL PNC solution were transferred to the electroporation cuvette 
(0.4cm, Sigma Aldrich) such that total 500μL volume contains sub-toxic concentration 
of PNC and above mentioned number of JCs. In parallel, two sets of 500μL JC 
suspension were also prepared for blank JC and electroporated blank JC, and 
transferred to electroporation cuvette (Merk Sigma Aldrich®). All PNCs were added to 
electroporation cuvette-containing JC suspension and subjected to electroporation 
(BIORAD Gene PulsorTM) at 250V and 250μF capacitance, and time constant (ms) 
was noted. After electroporation, samples were kept for minimum 5 minutes to allow 
resealing of cell membrane pores. JCs were centrifuged at 1000rcf for 5min and 
supernatant was collected. JCs were washed with RPMI, collected and immediately 
used for phototherapy and Confocal laser scanning microscopy (DMI6000 Leica TCS 
SP5; LSM880 Zeiss).  
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3. Quantification of mTHPP 
 
3.1. Amount of mTHPP complexed with polymer 
The amount of mTHPP which is complexed with each polymer was determined by 
direct and indirect methods. In case of direct method, mTHPP was extracted from 
mTHPP-PSS NC and mTHPP-PVP NC by ethanol and from mTHPP- Protasn® NC by 
isopropanol (spectrophotometric grade, Sigma Aldrich). For indirect method, free 
(uncomplexed) mTHPP on filter was dissolved in ethanol for mTHPP-PSS NC and 
mTHPP-PVP NC and in isopropanol (spectrophotometric grade, Sigma Aldrich) for 
mTHPP- Protasn® NC. Amount of mTHPP estimated by UV spectroscopy (Multiscan 
GO, Thermoscientific) in both methods were compared. For indirect method estimated 
amount of mTHPP was subtracted from the amount of mTHPP used for experiment.  
 
Amount of mTHPP complexed = Total amount of mTHPP added - Free mTHPP 
 
For direct estimation of mTHPP, 1mL each PNC was freeze dried in eppendorf tube. 
Extracting solvents each 1mL ethanol (mTHPP-PSS NC and mTHPP-PVP NC) and 
isopropanol (mTHPP-Protasn® NC) were added in eppendorf tube, vortexed and 
centrifuged at 2500rcf. Supernatant was collected and the process was repeated 
thrice with addition of respective organic solvent. Supernatants of each step were 
pooled and estimated by UV spectroscopy at 418nm.  
 
For indirect method, after filtration step as mentioned above, the moist filter was dried 
in oven at 40ºC, over 1hr. Then, ethanol (mTHPP-PSS NC and mTHPP-PVP NC) and 
isopropanol (mTHPP- Protasn®) were added on filter to dissolve free mTHPP and 
collected as filtrate under vacuum. These alcoholic solutions of mTHPP were further 
diluted and estimated by UV spectroscopy at 418nm. 
 
3.2. Amount of intra-Jurkat-cellular mTHPP complexed with polymer  
The amount of mTHPP internalized into JCs was determined by fluorescence 
spectroscopy (Fluostar Optima®). Three sets of JCs (80x104) in 500µL, each 
suspended in 31µg/mL (mTHPP-PSS NC), 47µg/mL (mTHPP-Chitosan NC) and 
94µg/mL (mTHPP-PVP NC) solutions in RPMI medium were subjected to 
electroporation at 250V current and 250µF resistance between 4-6ms time constant. 
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The JC suspensions were allowed to rest for minimum 5 minutes to allow resealing of 
pores. PNC loaded JCs were centrifuged at 1000rcf for 5 minutes followed by washing 
with RPMI medium to remove non-encapsulated PNCs. Cell lysing agent, 2% 
TritonX100 (100 µL) was added to cell pellet and vortexed to break down the cells. 
Ethanol for mTHPP-PSS NC and mTHPP-PVP NC, and isopropanol for mTHPP-
Chitosan NC (400µL) were added and further vortexed to extract out mTHPP from 
PNCs. Extraction mixtures were centrifuged at 1000rcf for 5 minutes and supernatant 
was collected. The procedure with ethanol and isopropanol was repeated thrice and 
all extracts were pooled together. Extracts were serially diluted in a light protected 96 
well plate. The amount of mTHPP internalised into JC was estimated from standard 
curves at λexc=415 nm and at λem= 670 nm against blank ethanol and isopropanol.   
 
3.3. Determination of complexation efficiency 
The amount of free mTHPP remaining on filter and complexed mTHPP was 
determined by UV-spectroscopy. CE in terms of ‘number of monomers binding to one 
molecule of mTHPP’ was calculated by converting the amount of mTHPP complexed 
with polymer to the molar ratio of mTHPP and number of monomers forming the 
complex. 
 
4. Characterization of mTHPP-Polymer NCs 
4.1. Spectral characterization 
As the PNC inherits both chemical and spectral features from their parent compounds 
i.e. mTHPP and respective polymer, therefore overall spectrums of mTHPP, each 
polymer and PNC were determined. mTHPP (1mg) was dissolved in 1mL ethanol and 
further diluted to produce 2μg/mL ethanolic solution of mTHPP. Ethanol (blank) was 
first scanned between 200 to 800 nm to set the baseline followed by 2μg/mL ethanolic 
solution of mTHPP. 
 
Each PNC (1mg) was weighed and individually dissolved in 1mL MilliQ water to 
produce 1mg/mL aqueous solution. After further dilution with MilliQ water, mTHPP-
PSS and mTHPP-PVP NCs solutions (5μg/mL) and mTHPP-Chitosan (500μg/mL) 
were produced. First, MilliQ water (blank) was scanned between 200 to 800nm to get 
the baseline and then 5μg/mL solutions of each PNC was scanned in same way to get 
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spectrums. Aqueous solutions of each polymer; PSS (20μg/mL), PVP (31μg/mL), and 
Chitosan-HCl or Protasan® (500μg/mL) were also scanned for UV spectrums.  
 
4.2. Molecular modeling characterization 
The molecules viz, mTHPP, PSS, PVP and Chitosan were sketched and minimized 
using Powell method in Sybyl X 2.1. Gasteiger-Hückel charges were applied to the 
molecules during minimization. Docking studies was performed using AutoDock Vina. 
 
4.3. Atomic force microscopy (AFM) 
Aqueous solutions of all PNCs were characterized for their surface morphology and 
size by AFM. The system runs by JPK software. The PNC solution was placed on the 
mica chip stuck on glass slide surface, with the help of a pipette and allowed to air dry. 
The slide was kept below the cantilever (silicon tip). Images were obtained by 
displaying the amplitude signal of cantilever in the trace direction and the height signal 
in retrace direction, both signals being recorded simultaneously. The images were 
recorded in height and 3D view, and particle size of 50 PNC images were manually 
counted by JPK software.  
 
4.4. Confocal laser scanning microscopy (CLSM) 
Delivery of polymeric photosensitizer PNCs into JCs was confirmed by CLSM. 
Subtoxic concentration of each PNC as determined by MTT assay was individually 
loaded into 80x103JCs by electroporation. JC suspension was taken into eppendorf 
tube and centrifuged at 1000rpm for 5 minutes. Supernatant was removed and cells 
were washed with medium to remove non-encapsulated PNC. JCs were fixed on slide 
with PBS/4% (w/v) paraformaldehyde. FluorSaverTM reagent (Merk Millipore®) was 
spread on smear of cells and covered with cover slip. Imaging of cells were carried out 
using two confocal laser scanning micrsocopes; DMI6000 Leica TCS SP5 for 50µm 
images and LSM880 Zeiss for 5µm images. In order to get 50µm images, mTHPP-
PSS NC, mTHPP-Protasan® NC and mTHPP-PVP NC loaded JCs were excited at 
458nm, 405nm and 458nm respectively while for 5µm images, all NCs were excited at 
440nm laser line. Emission wavelengths and image were recorded. 
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5. Cell culture studies 
 
5.1. MTT assay of polymeric nanocomplexes 
JC suspension (10,000 cells/200µL) was added in a V bottom 96 well plate. Next day, 
the plates were centrifuged at 1000rcf for 5 minutes to harvest JC in V bottom of the 
plate. Supernatant was carefully removed and 200μL serial dilutions (1:1) of 
1000μg/mL mTHPP-PSS NC, mTHPP-PVP NC and mTHPP-Chitosan NC were added 
to each well. After overnight incubation, the 96 well plate was centrifuged and 
supernatant was carefully removed followed by addition of 200μL MTT dye:RPMI (1:9) 
to each well. Incubation overnight leads to conversion of yellow MTT dye into violet 
tetrazolium salt crystals by the cell metabolites at the bottom. The plate was again 
centrifuged and supernatant was removed followed by addition of 200μL DMSO 
(Sigma Aldrich®) and stirring at 200rpm to dissolve the crystal. The solutions in each 
well were transferred to flat bottom 96 well plate and the intensity of dye was 
measured by spectrophotometer at 570 nm. 
 
5.2. Haemotoxicity studies of mTHPP-Polymer nanocomplexes 
Human blood was collected with the help of technician in a tube containing 150mg  
EDTA/100mL blood and centrifuged at 3500rcf to separate plasma and RBC at the 
bottom. The plasma was taken out and RBCs were washed twice with normal saline 
and diluted up to 10 times in normal saline. JC suspension (80x103 cells/500 µL) blank 
and loaded with mTHPP-PSS NC, mTHPP-PVP NC and mTHPP-Chitosan NC were 
added to RBC suspension (150x103 cells/500 µL) to make up total 1mL volume in an 
eppendorf tube. Distilled water was added to a set of RBC (150x103 cells) for positive 
control. All samples were incubated at 37ºC under 40rpm stirring. Each sample was 
centrifuged at 0.5, 6 and 12hr interval, and supernatant was collected. Supernatant 
contains Hb which is released due to breakdown of RBC and forms Oxy-Hb upon 
exposure to air. Oxy-Hb was estimated by spectrophotometer at 540nm. 
 
5.3. Blood clotting study 
Blood clotting study was performed using human blood by slide method. The finger 
was pricked with needle and immediately mixed with JC (80x103 cells/100µL); blank 
and loaded with mTHPP-PSS NC, mTHPP-PVP NC, and mTHPP-Chitosan NC. 
Formation of fibrin was tested every 30 seconds with needle and time was noted upon 
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fibrin formation. The experiment was performed at ambient temperature and controlled 
by clotting time estimation of only blood.  
 
5.4. Anticancer activity of NC loaded JC against A549 lung carcinoma cells 
A549 cells (10,000cells/well) were seeded in a 96 well plate one day before the 
experiment for both dark and laser induced toxicity studies. Next day, the sub-toxic 
concentrations of PNCs viz, mTHPP-PSS NC (31µg/mL), mTHPP-PVP NC (94µg/mL), 
and mTHPP-Chitosan NC (47µg/mL) were internalized into JCs by electroporation at 
250V and 250µF capacitance. For electroporation, JC suspensions (20x103, 40x103 
and 80x103 cells) in 250μL RPMI and 250μL PNC solutions were transferred to the 
electroporation cuvette and 250μL RPMI was added such that total 500μL volume 
contains sub-toxic concentration of PNC and 20x103, 40x103 and 80x103 JCs. 
Besides, 2 sets of JC suspension as blank JC (20x103) and, electroporated blank JC 
(20x103) in 500μL protein free RPMI medium were also prepared and transferred to 
electroporation cuvette. All samples were mixed gently and subjected to 
electroporation at 250V and 250μF capacitance, and time constant (ms) was noted. 
After electroporation, samples were kept for minimum 5 minutes to allow resealing of 
cell membrane pores. Then, JCs were centrifuged at 1000rcf for 5 minutes and 
supernatant-containing non-encapsulated PNC was removed and cell pellet was 
washed and suspended in 200μL medium. The medium of A549 cells (1x104 
cells/well) in 96 well plate was removed and each sample volume (200μL) was 
transferred to A549 cell and allowed to incubate over 4hr at 37ºC.  Then, 96-well plate 
was centrifuged at 1000rcf for 5min and supernatant was removed. The plates for light 
induced toxicity studies were irradiated (Lumundus Eisenach GmbH) at 457nm with 
light dose 12J/mm2. The light dose was calculated into J/mm2 by multiplying 40 Storm 
(mA) with 100W/m2 times duration of light exposure in seconds.  MTT dye (200µL; 
1part dye and 9parts RPMI medium) were added to each well and MTT assay was 
performed as mentioned in MTT assay procedure. 
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G. RESULTS AND DISCUSSION 
Nanocomplexes for anticancer therapy such as self-assembled micellar NC of 
catechin derivative with protein (Chung et al, 2014), Chitosan-micro RNA NC (Santos 
et al, 2015) and, siRNA and RNA-based CD30 aptamer probe co-complexed with 
nano-sized polyethyleneimine-citrate (Zhao et al, 2011) have been designed. 
However, targeting deeply localised tumours and malignancies are still challenge. A 
delivery system comprising polymeric mTHPP NC encapsulated in T lymphocytes is 
promising to successfully tackle the challenge because T cells have accessibility to 
even deeply seated cancer cells and photosensitizers having excitation peak between 
650 to 900 nm can be irradiated from a 7-14 cm distance (Mitsunaga et al, 2011 and 
Weissleder et al, 2003).  
 
Such a delivery system combining phototherapy and immunotherapy was formulated 
by first synthesizing polymer-mTHPP nanocomplex followed by internalization into T 
cells. We have used mTHPP as a model drug for mTHPC which is used in clinical 
practice as second generation photosensitizers and Jurkat cells (transformed T cells) 
to design a proof of concept focused on development of the delivery system aiming for 
photoimmunotherapy of cancer. Interplay of immune therapy mediated by T cells and 
photodynamic action exerted by the loaded photsensitizer nanocomplex can result in 
effective killing of cancer cells even if they are present in deep tissues.  
 
1. Analytical method development 
Quantification of the drug incorporated into the delivery system is one of the most 
important parts in formulation development. Different techniques are used for 
quantification such as UV, fluorescence spectroscopy, HPLC etc. We had chosen UV 
spectroscopy for quantification of mTHPP complexed with polymers because it is time 
saving, simple and easy technique. This quantitative information is important to not 
only know the amount of mTHPP complexed with polymer but also to calculate the CE 
of each polymer. The aim of the project is also extended to estimate the amount of 
mTHPP reached within JCs in form of polymer nanocomplex. As UV spectroscopy is 
not sensitive enough to accurately estimate the intracellular mTHPP, therefore a 
sensitive technique such as fluorescence spectroscopy was used for precise 
quantification. 
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2. Synthesis of Polymer-mTHPP NCs 
Water soluble NCs of mTHPP with different polymers were synthesised by merely 
mixing the aqueous solution of polymer with ethanolic solution of mTHPP. When 
aqueous solution of polymer and ethanolic solution of mTHPP are mixed together, a 
hydroalcoholic mixture is formed which consists of hydroalcoholic solvent containing 
both non-complexed mTHPP suspended as free drug and complexed mTHPP as 
water soluble mTHPP-Polymer complex. In fact, mixing of aqueous and ethanolic 
solutions allows free intermolecular interaction between mTHPP and polymer to 
associate each other through non-covalent bondings. 
 
Intermolecular forces arise from attraction or repulsion between molecules, atoms or 
ions. They are weaker than intramolecular forces which keep the whole molecule 
intact through co-valent bond formed by sharing of electrons. While the intermolecular 
interaction takes place, the level of potential energy changes; the ability of chemical 
entities taking part in complex formation is determined by their level of potential 
energy in electronic ground state (Schreck et al, 2016). Together mTHPP and all 
polymers (Fig.17, 18, 19, 20) are rich in mobile electrons in ground state. Presence of 
lone pairs of electron, H-atoms, dipoles between counterpart atoms; all of them are 
prerequisite for intermolecular interaction which leads to complexation.  
 
The intermolecular forces are either permanent arising from electrostatic attraction 
between dipoles such as H-bonding interaction, ion-dipole, π-π interaction or 
temporary force like van der Waals forces (Keesom force, Debye force, and London 
dispersion force) which arise due to interaction of uncharged atoms and molecules. 
 
The mobile electrons in chemical structure play key role in formation of nanocomplex 
and rich presence of non-covalent electrons enhance the tendency of complex 
formation. Interestingly, mTHPP possess plethora of mobile electrons and monomers 
of each polymer chain also have sufficient electrons which impart not only in complex 
formation through physical bonding but also able to be excited by laser to generate 
ROS for inducing phototoxic effect.  
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Looking at the chemical structures of mTHPP (Fig.17) and polymers (Fig.8, 9 & 10); 
the parent porphyrine ring in mTHPP is substituted at all four carbons of exocyclic 
double bond, each by the meta carbon of phenolic ring. mTHPP is rich in mobile 
electrons because of four benzene rings, four pyrrole rings, four exocyclic double 
bonds, and 8 lone pairs of electron together on nitrogen and oxygen. Moreover, 6 
hydrogens are bonded to nitrogen and oxygen. These mobile electrons in mTHPP 
molecule can form hydrogen bond with hydrogen atom of counterpart as well as π-π 
interaction between electropositive nitrogen atoms with π-electrons is also possible to 
produce charge transfer complex. 
 
Electronegativity difference between hydrogen and its electronegative oxygen creates 
permanent dipoles responsible for electrostatic interactions. Further, electropositive 
nitrogen can also induce dipole interaction with any encountered electronegative 
species. Thus, mTHPP is an ideal candidate for complexation with any other chemical 
entities possessing similar electronic and chemical attributes.  
   
On other hand, PSS monomer contains a benzene ring, 2 exocyclic double bonds, 
and a sulphonate group (Fig.17a). PVP monomer has a ketonic group which produces 
a permanent dipole in monomer and electropositive nitrogen atom (Fig.17b) helps 
inducing the dipole with encountered electronegative species which trigger complex 
formation. In case of Chitosan hydrochloride (Protasan®), 6 lone pairs of electron and 
hydrogen bonded with oxygen and hydrogen in monomer provoke it to predominantly 
undergo hydrogen bonding interaction (Fig.17c). Thus electronic and chemical 
features of each polymer enable them to undergo complexation, therefore they were 
chosen for nanocomplexation with mTHPP.  
 
An interplay of all these physical forces lead to complexation between complexing 
agents. Pichierri et al, have investigated dipole-dipole interactions in protein-protein 
complex taking Ubiquitin Dsk2 as model protein. The stability and correct alignment of 
protein complex was largely derived by dipole-dipole interaction (Pichierri et al, 2013). 
The empirical data depicting fingerprints of hydrogen bonding were studied which is 
responsible for complex formation between acetone and chloroform aziotrope 
(Schreck et al, 2016). The interactions between local anaesthetic bupivacaine and its 
structural analogues viz, 2,6-dimethylaniline and N-methyl-2,6-dimethylacetanilide, 
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cocaine  and electron deficient moieties were studied by UV-visible spectroscopy and 
proton-NMR. Red shift in UV-visible wavelength of electron acceptor and chemical 
shift in NMR indicated change in electron flow and formation of charge transfer 
complexes through π-π interaction between bupivacaine, its analogues and aromatic 
acceptors (Powell et al, 2007). Solubility enhancement study and complexation 
through π-π interaction were investigated between phenanthrene (π-electron donor) 
and quinones and N-heteroaromatic cations (π-electron acceptor) by UV-visible 
spectroscopy and proton NMR. Charge transfer bands in UV spectroscopy and ring 
current shifts in NMR spectrums confirmed π-π interaction (Wijnja et al, 2004). 
 
The mechanism of nanocomplex formation can be either explained by applying 
quantum mechanics, molecular mechanics or phenomenologically in view of above 
mentioned intermolecular forces such as dipole-dipole interactions, π-π interaction, 
van der Waals forces. Taking each polymer and mTHPP, the phenomena of 
nanocomplex formation, behaviour of polymer and mTHPP undergoing physical 
interaction from their chemical structure and molecular modelling are described. 
 
In case of mTHPP and PSS, nanocomplexation is majorly driven by H-bonding, π-π 
interaction as well as dipole interaction. All hydrogen bonded with oxygen of phenolic 
ring in mTHPP take part in forming hydrogen bond with lone pairs of electron present 
in sulphonyl moiety of PSS monomers. Nitrogen is electron acceptor moiety in mTHPP 
which forms charge transfer complex with π-electrons of benzene ring in PSS. All four 
hydroxyl groups of mTHPP and sulphonyl group of PSS form permanent dipole and 
mutually create dipole-dipole interaction (Fig.17a). 
 
In case of mTHPP-PVP nanocomplex, π-interaction from both counterparts is 
possible. Electropositive nitrogen of PVP forms charge transfer complex with π-
electrons of benzene ring, porphyrine ring and exocyclic double bonds in mTHPP and 
on other hand nitrogen of mTHPP undergoes π-interaction with π-electrons of 
carbonyl group. Moreover, lone pairs of electron on carbonyl forms hydrogen bonding 
with hydrogen bonded with oxygen in mTHPP molecule. All four hydroxyl group of 
mTHPP and a carbonyl group of PSS form permanent dipole and mutually create 
dipole-dipole interaction (Fig.17b).  
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mTHPP  
(complexed with PSS)  
(Water soluble) 
mTHPP  
(complexed with Chitosan)  
(Water soluble) 
 
mTHPP  
(complexed with PVP)  
(Water soluble) 
mTHPP in water  
(Insoluble and forms aggregate) 
 
Fig.16. Behaviour of mTHPP in water, alone and as complexed with polymer 
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Fig. 17: Polymer-mTHPP nanocomplex and mTHPC with one less π-bond encircled 
 
Chitosan is rich in lone pairs of electron on oxygen which forms hydrogen bond with 
oxygen bonded hydrogen of mTHPP. Beside, hydrogen of alcoholic group and 
electropositive nitrogen in Chitosan monomer can act as electron acceptor to interact 
with π-electrons of mTHPP to produce charge transfer complex. Further these 
hydrogen atoms of Chitosan form Hydrogen bondings with electronegative oxygen 
atoms of mTHPP (Fig.17c). 
(a) mTHPP-PSSNa nanocomplex (b) mTHPP-PVP nanocomplex 
(c)  mTHPP-ChitosanHCl nanocomplex (d)  mTHPC 
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Fig.18: Molecular model showing interaction of mTHPP and polystyrene sulphonate  
            Dotted line indicates bond distance in Aº 
 
Fig.19: Molecular model showing interaction of mTHPP and polyvinylpyrrolidone 
                    Dotted line indicates bond distance in Aº 
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Though these polymers are capable to form complex with mTHPP through various 
intermolecular interactions, the efficiency of a polymer in complex formation varies and 
largely depends upon the number of mobile electrons associated with aromatic 
characters. Complexation efficiency study revealed PSS as the most efficient polymer 
in formation of nanocomplex than Chitosan and PVP. Chitosan is more efficient than 
PVP for the same reason. Reasons behind varying complexation efficiencies of 
polymers following the order mTHPP-PSS NC > mTHPP-Chitosan NC > mTHPP-PVP 
NC are explained later.  
 
We had also performed computer aided drug design studies to investigate 
intermolecular interaction between mTHPP and respective polymers. This study had 
been carried out only up to a preliminary stage to get rudimentary data. Further 
studies are underway until getting molecular modelling parameters which are 
comparable against spectrophotometric results. This can precisely unravel the 
behaviour of each polymer and mTHPP in aqueous solvent. Based on preliminary 
studies all molecular models (Fig.18, 19 & 20) show H-bonding and π-π interactions 
as most energetically favourable. In case of mTHPP-PSS NC, π-π and H-bonding 
interactions are evident while mTHPP-Chitosan NC shows only H-bonding. 
Interestingly, mTHPP-PVP shows poor H-bonding interaction and key interactions are 
Fig.20: Molecular model showing interaction of mTHPP and Chitosan in their nanocomplex 
             Dotted line indicates bond distance in Aº 
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governed by hydrophobic forces e.g. van der Waals interaction between pyrrolidone 
and phenyl rings of the THPP.  
 
Choice of mTHPP as a model drug for mTHPC which is second generation 
photosensitizer is due to cheap availability of mTHPP and very close physicochemical 
features to that of original drug (Fig.17d). Further, the freeze drying method was 
adopted to prepare nanocomplex because this method appeared to be more efficient 
in nanocomplex formation (Reum et al, thesis 2011).  
 
In process of development of a drug-delivery system, journey starts from 
preformulation studies through solubility and permeability profiling of drug molecule. 
As our T lymphocyte based delivery system is intended to be administered directly into 
blood therefore permeability profile is ruled out but enhancing aqueous solubility of 
mTHPP is indispensable. Aqueous solubility of mTHPP is highly desirable in T cell 
based formulation development because mTHPP forms aggregate in water (Fig.16). 
This presents hurdle in formulation development especially when internalizing mTHPP 
into Jurkat cells, it must be soluble in medium so that a suitable Tcell based 
formulation can be developed. Moreover, poor aqueous solubility of mTHPP instigates 
accumulation in tissues where it slowly releases and degrades causing toxicity. 
 
 
 
 
 
 
 
 
Several approaches based on nanotechnology principle have been applied to solve 
poor aqueous solubility problem of challenging and difficult-to-deliver drug molecules. 
Kumar et al have improved aqueous solubility of amphotericin B (Italia et al, 2009) and 
Water soluble drug-polymer complex chain 
Water soluble moiety 
Water soluble polymer chain 
Water insoluble drug molecules 
(water insoluble) 
Fig.21. Solubility enhancement model; water soluble polymer and water insoluble drug forms  
              water soluble drug-polymer 
              nanocomplex 
Non-covalent 
bonding 
bonding 
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cyclosporin (Italia et al, 2007). Solubility of Paclitaxel was improved by formulating 
stable PEGylated liposome (Yang et al, 2007). We had approached nanocomplexation 
technology to enhance aqueous solubility of mTHPP because NCs have produced as 
smaller size particle as 10-80 nm (Table 5; Fig.26a, 26b, 27a, 27b, 28a, 28b) and 
weak physical bonds alongwith high intensity of laser during photodynamic therapy 
facilitates faster release of mTHPP.  
 
NCs must exhibit polarity which is prerequisite for aqueous solubility; PSS possess 
sulphonate group where electronegativity difference of O and S generates polarity 
between them, similarly PVP possess polarity due to electronegativity of O in ketonic 
group and amine salt group confers polarity to Chitosan hydrochloride (Protasan®). 
Intermolecular interaction of water insoluble mTHPP with these polymers produces a 
complex with altered solubility. 
 
Infact, after formation of complex water soluble moiety responsible for aqueous 
solubility of polymers greatly imparts in making the nanocomplex water soluble and 
thereby increases solubility of mTHPP. According to solubility enhancement model 
(Fig.21), non-covalent bonding between water insoluble drug and water soluble 
polymer form complex and compel the drug molecule to become aqueous soluble. 
However, CE of polymer determines the extent of water solubility of mTHPP (Table.5). 
When CE of polymer is higher, all monomers together in a polymer chain bind with 
relatively more number of mTHPP leading to enhanced aqueous solubility. 
 
3. Complexation efficiency study 
While the complexation takes place between polymer and drug, monomers in the 
polymer chain exclusively take part in complex formation. As the number of monomers 
taking part in formation of complex with one drug molecule decreases, polymer 
becomes more efficient in formation of complex with given drug molecule. On 
contrary, number of drug molecules forming complex with a polymer chain or number 
of monomers in single polymer chain can also describe complexation efficiency in 
terms of drug molecule.  Thus, Complexation efficiency (CE) in terms of monomers is 
defined as number of monomers in a polymer chain required to complex with one 
molecule of drug. Lower the CE value, more efficient is the polymer to form complex 
with drug. CE was determined from amounts of mTHPP and polymer taking part in 
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formation of complex. A molar ratio of mTHPP and polymer complexed with each 
other results in complexation ratio which defines CE of polymer.  
 
Moreover, taking 10:15 (drug:polymer) ratio for nanocomplexation shows different 
amounts of mTHPP complexed with respective polymers (Fig.22). Both the amount of 
mTHPP complexed and respective CE of polymers calculated follows the order of 
PSS>Chitosan>PVP (Table 5). 
 
 
Fig.22.   Comparison of amount of mTHPP complexed with different polymers by direct and indirect  
              methods. (Values are shown as mean of 2 independent experiments) 
 
Complexation efficiency of PSS is higher than PVP and Chitosan because in case of 
PSS, 6 monomers are required to form complex with one molecule of mTHPP while 
Chitosan and PVP need 14 and 27 monomers respectively to complex with one 
molecule of mTHPP. The benzene ring in PSS greatly increases aromatic character 
and thereby chances of π-π interaction and formation of charge transfer complex 
increases than other counterpart polymers. In addition, three lone pairs of electrons 
and two double bonds in sulphonate group also increase the probability of physical 
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interaction through dipole interaction and hydrogen bonding interaction. Thus, PSS 
appears to possess highest CE than PVP and Chitosan. Chitosan monomer with 9 
lone pairs of electron and 5 hydrogen atoms exhibit stronger CE than PVP monomer 
which possesses only a ketonic group (Fig.17, 18, 19, 20).  
Interestingly, molecular modelling of mTHPP and PVP reveal poor H-bonding and 
hydrophobic interaction (van der Waals forces) which can be attributed to its weakest 
CE than its counterpart polymers viz, PSS and Chitosan. Beside molecular model of 
mTHPP-PSS shows both H-bonding and π-π interactions against mTHPP-Chitosan 
which exhibit only H-bonding, suggest that CE of mTHPP-PSS is stronger than 
mTHPP-Chitosan. Thus order of CE among all polymers is mTHPP-PSS NC > 
mTHPP-Chitosan > mTHPP-PVP (Fig.18, 19, 20). 
Table 5: Size, zeta potential and CE of all mTHPP-Polymer NCs 
Nanocomplex 
Particle size*         
(nm) 
Zeta potential         
(mV) 
CE** 
mTHPP-PSS NC 65 ± 5 nm -  47  ± 12.0 05.78 ± 0.12 
mTHPP-Chitosan NC 80 ± 8 nm + 51  ±  9.0 14.28 ± 3.40 
mTHPP-PVP NC 10 ± 4 nm +3  ±  0.6 27.48 ± 2.84 
* Size were measured by manually counting 50 particles in AFM image 
**CE is number of monomers/mTHPP molecule  
 
4. Spectral characterization 
Spectral characterization by UV spectroscopy has shown unique spectral features in 
respective spectrums of each nanocomplex (Fig. 23, 24, 25). Interaction between 
mTHPP and polymers on electronic level changes mobility of electrons resulting in 
absorbance shifts. The absorbance maxima of mTHPP is 418 nm in alcohol; in case of 
mTHPP-PSS NC peak sifts to 446 nm and of mTHPP-PVP NC towards 423 nm (red 
shift) while mTHPP-Chitosan NC shifts towards 412 nm (blue shift).  
Apart from λmax of each Polymer-mTHPP NC, the absorbance peak above 600 nm is 
very important. The sensitivity of photosensitizers is greatly enhanced within near 
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infrared radiation fluorescence (NIRF) i.e. between 650 to 900 nm and penetration 
depth up to 7-14 cm in tissues and this range is also used in clinical practice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
e) UV spectrum of Chitosan HCl-mTHPP nanocomplex (5 µg/mL) 
Fig.22. UV spectrums of a) mTHPP, Chitosan HCl and mTHPP-Chitosan NC 
a) UV spectrum of mTHPP in EtOH (2µg/mL) 
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c) UV spectrum of mTHPP-PSS-Na nanocomplex in water (5µg/mL) 
Fig.23: UV spectrums of a) mTHPP, PSS-Na and mTHPP-PSS NC 
a) UV spectrum of mTHPP in EtOH (2µg/mL) b) UV spectrum of PSS-Na in water (20µg/mL) 
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c. UV spectrum of mTHPP-ChitosanHCl NC (500 µg/mL) 
Fig.24: UV spectrums of mTHPP, ChitosanHCl and mTHPP-ChitosanHCl NC 
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b) UV spectrum of PVP in water in (31 µg/mL) a) UV spectrum of mTHPP in EtOH (2µg/mL) 
 c) UV spectrum of mTHPP-PVP NC (5 µg/mL) 
Fig.25: UV spectrums of a) mTHPP, PVP and mTHPP-PVP NC 
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As evident from spectrums of all nanocomplexes; they show an absorbance peak in 
NIR range (600-900nm). mTHPP-PSS NC shows an absorbance at 685nm, mTHPP-
Chitosan shows bimodal peak at 607 and 677 nm while mTHPP-PVP NC shows at 
650 nm.  The absorption of light by Haemoglobin, lipids and auto fluorescence are 
minimal between 650-900 nm and therefore light above 600 nm can penetrate deep 
seated tissues from 7-14 cm (Mitsuganga et al, 2011 and Weissleder et al, 2003).  
Hence, absorbance peaks above 600 nm in each nanocomplex can be used in clinical 
application for deep seated tumours and malignancies. However, we had used λmax of 
each NC for our experiment in vitro pertaining to investigation their photodynamic 
activity because the size of JC is only about 8µm and targeted cancer cells lie in very 
close proximity.  
 
In view of these spectral features, all NCs hold candidature for clinical application in 
photodynamic therapy. Further, smaller size of PSS (Mw=4.3 KDa) against Chitosan 
HCl (Protasan®, Mw=100 KDa) and PVP (Mw=31 KDa) strengthen its candidature as 
an ideal excipient for polymeric NC because after metabolism, smaller molecular size 
facilitates faster renal clearance. 
 
Table 6: Physical, spectral properties and CE of Polymer-mTHPP NCs 
 
Drug and its nanocomplex 
Spectral characteristic 
(UV-λmax) 
Physical characteristic 
(Colour) 
mTHPP 418 nm violet 
mTHPP-PSS NC 446 nm dark green 
mTHPP-PVP NC 426 nm Light (violet to yellow) 
mTHPP-Chitosan NC 412 nm light green 
 
Due to weak physical forces between polymer and mTHPP, they can dissociate into 
the cell but such dissociation does not alter the photodynamic potential as NC and 
dissociated mTHPP, both possess peaks above 600 nm for excitation to exhibit 
fluorescence which is essential for photodynamic effect. Moreover, distinct colours of 
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each nanocomplex are their unique physical attributes for preliminary identification. 
The colour of mTHPP-PSS NC is dark green while mTHPP-PVP appears light yellow 
to violet and mTHPP-Chitosan light green (Table 6). 
 
5. Particle size, morphology and surface charge 
In view of internalization of each Polymer-mTHPP NC into Jurkat cells, 
characterization in terms of particle size measurement and determination of surface 
charge are crucial. Particle size greatly influences the passage of drug molecules 
through biological membrane inside cell. Cell membrane bears negative charge, 
hence surface charge on NC is also an important criterion to determine capability for 
intracellular delivery. Thus, size and surface charge greatly influence cellular uptake. 
 
Ideally smaller size and positive charge must facilitate uptake of NC into JCs, however 
positive charge also causes damage to cellular structure (Fröhlich et al, 2012). Atomic 
force microscopy revealed morphology (Fig.26a&b, 27a&b, 28a&b) as well as size of 
each NC. As fluorescence exhibited by NC interferes with the dynamic light scattering, 
therefore size data rely exclusively upon counting 50 particles by Atomic force 
microscopy. 
 
The size of mTHPP-PVP is much smaller (10 nm) with discrete particles than other 
two NCs; Chitosan-mTHPP (65 nm) and mTHPP-PSS (80 nm) (Table 5; Fig.26a&b, 
27a&b, 28a&b). PSS monomer is much bigger than other counterparts; therefore its 
size is larger (80 nm). Overall size of NCs lie within 10-80 nm range is smaller enough 
to facilitate their internalization into JCs. 
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Fig.26a: AFM image of mTHPP-PSS nanocomplex (1x1 µm) 
 
Fig.26b: 3D view; AFM image of mTHPP-PSS nanocomplex (1x1 µm) 
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Fig.27a:  AFM image of mTHPP-Chitosan HCl nanocomplex (0.5x0.5 µm) 
 
 
 
Fig.27b: AFM image of mTHPP-Chitosan HCl nanocomplex (0.5x0.5 µm) 
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Fig.28a: AFM image of mTHPP-PVP nanocomplex (2.5 x 2.5 µm) 
 
Fig.28b: AFM image of mTHPP-PVP nanocomplex (2.5 x 2.5 µm) 
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6. Confocal laser scanning microscopy 
Confocal scanning microscopy is a tool to confirm intracellular delivery of fluorescent 
compounds. Electroporation internalizes NCs into JCs where they exhibit fluorescence 
upon excitation by laser. Looking at absorption spectrums (Fig.23, 24 & 25) of each 
NC, it is evident that all NCs have similar spectral properties due to presence of 
common photosensitizer (mTHPP) associated with different polymers which have 
merely changed the electron mobility of mTHPP to make different but yet similar NCs.  
 
             
 
             
 
50µm 
50µm 
5µm 
5µm 
Fig.29: Confocal image of mTHPP-PSS NC loaded JC (λexc = 458nm; λem = 530-560nm) 
λexc = 458nm; λem = 530-560nm λexc = 440nm; λem = 482-606nm 
Fig.30: Confocal image of mTHPP-Protasan
®
 NC loaded 
λexc = 440nm; λem = 455-580nm λexc = 405nm; λem = 470-520nm 
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7. Cell culture studies 
7.1. Cellular toxicity studies 
Cellular toxicity studies were performed on Polymer-mTHPP NC and electroporated 
blank JC. When the Polymer-mTHPP NCs have internalized into JC, their 
concentration must not affect viability of cells. Therefore, safe concentration of 
nanocomplex to JC for safe intracellular delivery was determined by dark toxicity study 
of Polymer-mTHPP NC with JC. 
  
On other hand, while JC are subjected to electroporation, electric impulses are 
generated to form pores in the cell wall which can damage the cell resulting in cellular 
death. Therefore, optimization of electroporation parameters is equally important. 
Thus, overall objectives of cellular toxicity studies are optimization of sub-toxic 
concentration of Polymer-mTHPP NC and electroporation parameters for safe 
intracellular delivery of PNC into JC to develop an active, viable and efficient delivery 
system. 
 
Comparison of dark toxicity profile of each NC by MTT assay of JCs showed toxicity in 
order of mTHPP-PSS > mTHPP-Chitosan > mTHPP-PVP (Fig. 32). The highest 
toxicity of mTHPP-PSS in comparison to its counterparts is attributed to its lower CE 
value in terms of monomers. 
50µm 5µm 
Fig.31: Confocal image of mTHPP-PVP NC loaded 
λexc = 440nm; λem = 448-577nm λexc = 458nm; λem = 497-515nm 
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Fig. 32: In vitro dark toxicity of Jurkat cells (1x10
4
) following incubation with serial dilutions of 1000 
             µg/mL PSS NC, mTHPP-PVP NC and mTHPP-Chitosan NC 
  (Values are representative of 3 independent experiments and reported as mean ± S.D.) 
 
In order to form a NC with one mTHPP molecule, 6 PSS monomers are required while 
for mTHPP-PVP NC 27 monomers and for mTHPP-Chitosan 14 monomers are 
needed. Taking a chain of each polymer with equal number of monomers, PSS carries 
more numbers of mTHPP molecules than Chitosan and then PVP in their NC (Fig. 
33). These monomers form physical bonding with mTHPP molecule and the 
mechanism of formation of intermolecular forces leading to nanocomplexation is 
described previously. 
 
Interestingly, Chitosan is more toxic to cells due to amine cationic head than 
negatively charged PSS and neutral PVP polymers but after complexation with 
mTHPP the toxicity profile is altered. It can be attributed to mTHPP which plays key 
role in determining the toxicity to exposed cells. Chitosan having lower CE carries less 
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number of mTHPP in its NC than mTHPP-PSS, therefore later surpass the toxic 
potential over mTHPP-Chitosan due to its stronger CE.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 33:  Schematic representation of mTHPP-Polymer NCs showing molecular interaction between  
             mTHPP and a polymer chain segment containing 28 monomers.  
 
 
PVP is an inert and biocompatible polymer, and used as plasma volume expander 
(Motif, 1975). The CE of PVP is weakest among all PNCs, as evident from acquisition 
= Monomer 
(a) ∼ 28 monomers of PSS bind with 6 mTHPP molecule 
(b) ∼ 28 monomers of Chitosan HCl bind with 2 mTHPP molecule 
(c) ∼ 28 monomers of PVP bind with1 mTHPP molecule 
= Polymer chain = mTHPP = non-covalent bond 
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of lowest amount of mTHPP for complexation out of the total mTHPP amount taken for 
experiment (Fig.22). Hence, mTHPP-PVP NC appears least toxic than its 
counterparts.  
 
Despite a significant toxic potential in PDT associated with mTHPP-PVP and mTHPP-
Chitosan NCs, a huge amount of polymer is required as an excipient which may in 
turn increases the cost of formulation. Thus PSS holds an ideal candidature for an 
excipient in polymeric NC based formulation of mTHPP among PVP and Chitosan, as 
previously explained. A schematic molecular model of PNC (Fig.33) vividly depicts the 
comparative mTHPP dependent toxic potential of all PNC. Taking ∼28 monomers of 
each polymers complexing with mTHPP, PSS acquires 6 mTHPP molecule for 
complexation while chitosan forms complex with 2 mTHPP molecules and PVP with 
only 1 molecule. Thus the schematic molecular model and dark cytotoxicity results 
unravel the toxic potential of all 3 PNC following the order mTHPP-PSS > mTHPP-
Chitosan > mTHPP-PVP. 
 
Electroporation technique involves formation of nanosized pores in cell membrane 
using strong electrical fields, making cell membrane permeable with altered 
homeostasis (Rubinsky et al, 2007). Electroporation method was chosen for efficient 
delivery of Polymer-mTHPP NC into JCs because it is time saving, economic and 
involve only physical parameters in comparison to other biochemical methods in which 
use of chemicals can possibly alter physicochemical properties and influence 
intracellular delivery of Polymer-mTHPP NC. Upon comparing the viability of blank JC 
against electroporated JC (1x106 cells), later had shown 88% viability at 250V current, 
250μF capacitance at 6.7ms time constant (Fig.34) 
 
7.2. Intra-Jurkat-cellular quantification of mTHPP 
Quantification of mTHPP delivered into JCs consists of two major steps; retrieval of 
mTHPP-Polymer NC from JC by cell lysis followed by extraction of mTHPP from 
polymer. Cell culture studies pertaining to investigation of xenobiotic metabolite 
cellular lysis and extraction are very important for investigations of cellular xenobiotic 
metabolite (Myers et al, 2011) and materials to be delivered into cell.   
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Triton X 100 is non-ionic surfactant and commonly used in cellular studies for cell 
lysis. The procedure makes use of 2% TritonX 100 (which breaks down cellular 
structure to isolate polymeric nanocomplexes and addition of ethanol (for mTHPP-
PSS NC and mTHPP-PVP NC) and IPA (for mTHPP-Chitosan NC) resulted in further 
isolation of mTHPP from polymers. As the intracellular drug is often scanty therefore, 
fluorescence spectroscopy which is sensitive technique to quantify meagre amount of 
drug, was preferably used to estimate mTHPP.  
 
Safe concentration of each NC; mTHPP-PSS NC (31µg/mL), mTHPP-Chitosan NC 
(47µg/mL) and mTHPP-PVP NC (94µg/mL) as determined by MTT assay were used 
for intra-Jurkat-cellular delivery. Electroporation causes accessibility of mTHPP to 
intracellular milieu in the form of complex with polymer. Breaking cells followed by 
isolating mTHPP from each polymer is challenging due to 2 steps extraction. 
However, the detergent TritonX 100 and ethanol/IPA served this purpose to estimate 
mTHPP as 0.39-0.53pg/cell upon taking 80x103 JC for electroporation with all 
mTHPP-Polymer nanocomplexes (Table 7). The mTHPP taken up by all Polymer-
mTHPP nancomplexes was between 4.7-5.6% and estimated dose of mTHPP to kill 
75-80% A549 cells (1x104) by 80x103 JC ranges between 31-42 ng (Table.7).  
 
Table 7: mTHPP uptake by JC by electroporation 
mTHPP-Polymer 
NC 
mTHPP uptake  
(%) 
mTHPP/JC 
 (pg) 
mTHPP/80K JC 
 (ng) 
mTHPP-PSS NC 5.1 ± 1.6 0.4 ± 0.12 31 ± 9 
mTHPP-Chitosan 
NC 
5.6 ±  0.9 0.5 ± 0.08 42 ± 8 
mTHPP-PVP NC 4.7 ±  0.9 0.5 ± 0.10 39 ± 8 
Values are representative of 3 independent experiments reported as mean±S.D.   
 
 
Upon escalating both, the concentration of nanocomplex as well as JC number taken 
for intracellular delivery, the cellular uptake of mTHPP must increase. If concentration 
of mTHPP-Polymer NC is increased beyond safe concentration then it can lead to 
cellular toxicity therefore amount of NC/mTHPP to be delivered is restricted only to 
safe concentration and techniques like electroporation can deliver up to 4.7-5.6% 
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mTHPP. In order to enhance the T lymphocyte-encapsulated amount of 
photosensitizer by increasing the number of JCs is feasible. Thus, in clinical practice 
the dose of photosensitizer can be optimised by varying the number of T lymphocytes 
for intracellular delivery depending upon cancer cells counting in blood or tumour 
volume. 
 
 
 
Fig. 34: Viability testing of electroporated 2x10
4
 Jurkat cells reported as mean ± S.D., n=4 
 
7.3. Haemocompatibility studies 
T cells expresses Fc receptors which mediates antibody-dependent cytotoxicity 
leading to destruction of target cells through interaction between target-specific 
antibodies and Fc receptors (Landazurimo-De et al, 1979). Erythrocytes are known to 
be victim of immune system such as subsets of T cells bearing Fc receptor can break 
down erythrocytes (Katz et al, 1980). As T cell encapsulating Polymer-mTHPP NC is 
intended for direct administration into blood, encounter of T cells with RBC is evident. 
Therefore, the stability of the formulation in blood circulation and safeguard of blood 
cells from the T cell based delivery system are important. 
 
Cellular wall acts as barrier and allows intracellular and extracellular transport of drugs 
and other material by various mechanisms such as passive diffusion and carrier 
mediated transport (Sugano et al, 2010). Polymer-mTHPP NC may undergo passive 
diffusion to exit JCs because of concentration gradient across cellular membrane. The 
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size of Polymer-mTHPP NC is similar to other endogenous substances like DNA and 
viruses (Wang et al, 2008), therefore its active diffusion outside T lymphocytes in 
blood is inevitable. mTHPP and polymer are bound together with weak forces 
therefore NCs can dissociate into mTHPP and polymer. Chitosan has a cationic head 
and PSS possess negative charge. They may again form ion pair complex as well as 
free mTHPP may complex with substrates present in cell membrane, and undergo 
carrier mediated efflux from parent T cells (Ruifrok et al, 1981; Poirier et al, 2008). 
 
 
Fig. 35: In vitro hemolysis following incubation of human RBCs with 15 x10
4
 cells Blank JC, mTHPP- 
             PSS NC, mTHPP-PVP NC and mTHPP-Chitosan HCl loaded JCs in normal saline. Positive 
            Control shows 100% haemolysis (all values reported are mean ± S.D., n=4). 
 
All pathways leading to free mTHPP or NC escape from its T lymphocyte homing 
could be toxic to other blood cells. The extent of any adverse effect exerted through all 
diffusion pathways of NC, dissociated moieties and Jurkat cell itself while NC loaded 
Jurkat cell is present in blood was investigated by haemocompatibility studies viz, 
haemotoxicity studies and blood coagulation test (Fig.35 & Table 8). 
 
The haemolysis study was designed by taking 150x103 each blank JCs and JCs 
(20x103) loaded with mTHPP-PSS NC, mTHPP-PVP NC and mTHPP-PSS NC in 
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normal saline (NS) against positive control (RBC with distilled water). Erythrocytes 
maintain its integrity in normal saline due to osmolality over incubation up to 12hr.  
 
In case of positive control, addition of distilled water brings imbalance in fluid across 
erythrocyte cell membrane and transfer of extracellular fluid in RBC leads to cellular 
burst and death releasing Hb, is considered as 100% haemolysis used for estimation 
of haemotoxicity (Fig.35). Despite intact erythrocytes in NS, haemolysis only up to 
14% after 12hr shown by blank and NC loaded JC is due to ATP release induced by 
experimental condition which involve varying level of oxygen, sheer stress while 
samples are under stirring (Sikora et al, 2014) at 40 rpm and haemotoxicity exhibited 
by JC (Arber et al, 1978). Overall haemolysis profiling indicates protective role of the T 
cell based delivery system in blood (Italia et al, 2009). 
 
Table 8: Blood clotting studies with all Polymer-mTHPP NC 
Samples Time (Seconds) 
Blood 
 
130 ± 5 
 
Blood with mTHPP-PSS NC 
loaded JC 
 
129 ± 7 
 
Blood with mTHPP-PVP NC 
loaded JC 
 
130 ± 4 
 
Blood with mTHPP-Chitosan 
NC loaded JC 
 
122 ± 5 
Values are representatives of 3 independent experiments and reported as mean±S.D. 
Blood clotting is one of the host defence mechanism facilitating the repair of damaged 
vascular system. As leukocytes (e.g. T cells), erythrocytes and platelets are main 
player of blood clotting mechanism, therefore presence of T cell based delivery 
system may provoke the internal blood clotting. Blood clotting is assessed by the 
formation of fibrin fibres which arrest platelets and a platelet plug is formed appearing 
as clot. This platelet plug was checked every 30 seconds by needle for normal blood 
and those mixed with Polymer-mTHPP NCs loaded JC. Blood clotting studies showed 
the clotting time in presence of all three Polymer-mTHPP NCs loaded JC close to 
normal blood clotting time (Table 8). All mTHPP-Polymer NCs have shown no 
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deviation from the clotting time of normal blood i.e. 130 seconds which indicates 
protective role of cell based delivery system in systemic circulation. 
 
7.4. In vitro anticancer activity 
The phototoxic potential of all PNCs and intracellular released mTHPP from PNC, and 
ability of T lymphocytes to recognise and attack cancer cells were exploited together 
to kill A549 carcinoma cells. JC are transformed T lymphocytes (Schneider et al, 
1977) acted as model cell for T lymphocytes and mTHPP as model drug for mTHPC. 
  
Among all types of nanocarrier for delivery of mTHPP, nanocomplex is preferably 
chosen due to complex state of drug and polymer conjugate. As nanocomplex is 
merely association of mTHPP and polymer through physical bondings which may 
facilitates immediate release of mTHPP under certain condition. Other nanocarriers 
such as PEGylated moiety which helps accumulation of drug at tumor site, a stearic 
hindrance between cancer cells and nanocarrier appears which reduces tumor cell 
uptake (Gabizon, 2001 & Hatakeyama et al, 2007). Polymeric nanoparticles of 
therapeutics with polymers such as PLGA or PLA forms polymer matrix in which drug 
is entrapped. Such nanoparticulate structure may not allow full exposure of drug to 
laser and even after exposure to light, fluorescence quenching is inevitable. It can 
increase the dose of drug to get desired anticancer photodynamic effect and thereby 
the cost of photodynamic treatment.  
 
Moreover polymeric nanoparticles provoke sustained release of drug while in PIT, 
instant release of drug is desirable. On contrary, weak physical forces in 
nanocomplexes allows faster release of drug inside cell and interestingly the release is 
boosted under high intensity laser beam which can break down weak physical bonding 
to free mTHPP from polymer. Beside, any drug remaining bound with polymer itself is 
a fluorescent nanocomplex which is capable to exhibit photodynamic toxicity to 
destroy cancer cells.   
 
The whole anticancer study comprises of two sets viz, dark toxicity study and laser 
induced toxicity study. In each set 20x 103, 40x 103 and 80x103 JCs were used which 
include blank JC, electroporated blank JC and JC individually loaded with all three 
PNCs and only 10x 103 A549 cells as negative control. In laser induced toxicity study, 
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cells were irradiated by 457nm wavelength at light dose 12J/mm2 while dark toxicity 
samples were kept strictly away from any exposure to light (Fig.36). 
 
The phototherapy with all three PNC loaded JCs at 457nm and light dose 12J/mm2 
shows different levels of toxicities. As the number of NC loaded JCs undergoing 
phototherapy exponentially increases from 20x103 JC to 80x104 JC, the anticancer 
activity also proportionally increases; together all 3 PNC loaded JCs (20x104) shows 
A549 toxicity between 49-53% and if all 3 PNC loaded JCs (40x103) are taken then 
exhibit 61-63% toxicity. Further upon taking all 3 PNC loaded JCs (80x103) a toxicity 
range between 75-80% is shown which is a significant toxic effect exerted on A549 
cancer cells by immune cell based delivery system. Thus, the dose for a significant 
anticancer activity against 10x103 A549 cells was optimised as 31-42ng mTHPP 
encapsulated in 80K JC excited by 457nm light with 12J/mm2 intensity. When PNC 
loaded JC number increases the dose of photosensitizer NC increases and under 
optimised LED (light emitting diode) parameters show an increased phototoxic effect. 
This indicates that the level of cancer cell toxicity is photosensitizer-dose dependent at 
optimized light dose (12J/mm2) and the dose can be enhanced by increasing the 
number of JC encapsulating PNC. 
 
The sub-toxic concentration of different PNCs against JC was first optimised in MTT 
assay (dark toxicity study). The toxicity exhibited by all PNCs is substantially due to 
mTHPP rather than polymer, therefore the subtoxic concentrations of all 3 PNCs 
contain almost same amount of mTHPP. Further, the mTHPP which is bound to 
respective polymers with weak physical bonds releases in JC homing alongwith 
nondissociated mTHPP which remains as PNC, both play active role to exert 
photodynamic activity. 
 
Interestingly, mTHPP and PNC both are fluorescent and possess phototoxic effects, 
therefore upon excitation at 457nm, A549 cells are killed as a result of excitation of 
both released mTHPP and nondissociated mTHPP (nanocomplex). The A549 toxicity 
exerted by each PNC within same number of PNC loaded JC are almost comparable, 
however a relatively more anticancer effect associated with mTHPP-PSS NC is due to 
close matching of its λmax=446 nm  with excitation wavelength λexc=457nm of laser in 
comparison to mTHPP-Chitosan NC; λmax=412nm and mTHPP-PVP NC; λmax=426nm.  
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Fig.36: In vitro LED induced anticancer studies following, incubation of 20x10
3
 – 80x10
3
 JCs with 
            10x10
3
 A549 cells over 4 hours, and irradiation at 457nm, light dose 12J/mm
2
. 
            Blank (control) =A549 cells, B-JC=Blank JC, EB-JC=Electroporated blank JC,  
          PSSN-JC= mTHPP-PSS NC loaded JC, CHITN-JC= mTHPP-Chitosan loaded JC 
            PVPN-JC=mTHPP-PVP loaded JC. Control shows 100% toxicity 
            Values represent 3 independent experiments and reported as mean ± S.D. 
 
In vitro experimental condition provides an environment where JC remain in close 
proximity with A549 cells and JC binding with A549 cells through Tcell receptor is also 
possible. Thus, blank JC and electroporated blank JC show viability between 176-
193% which is additive viabilities of A549 cell and JC.  
 
Upon comparing light induced toxicity against dark toxicity, the phototoxic effect of 
PNC loaded JC on A549 cells during phototherapy is evident. In addition, together the 
electroporated blank JC and all 3 PNC loaded JC have shown a reduced viabilities in 
comparison to blank JC. As electroporated blank JC are killed during electroporation 
therefore they show 176% viability against 193% viability of blank JC which is due to 
the electroporation effect at optimised electroporation parameters on blank JC (Fig. 
36).  
Thus, the anticancer activity utilizing together the photosensitivity of PNC and, 
immunotoxic potential of JC is proven. Further this photo-immune cell based delivery 
system holds strong promise in an effective and safe photoimmunotherapy of cancer. 
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H. CONCLUSION 
 
 Nanocomplexation of poorly soluble drug like mTHPP with water soluble polymer 
enhances aqueous solubility of the drug which not only overcomes the problem in 
formulation development but also supress physiological limitations like 
accumulation and toxicity in tissues.  
 
 As the ever expanding field of cancer therapy face several challenges, can be well 
confronted by exploiting the combined principles of PDT and adoptive cell based 
therapy for a safe, effective and economic management of cancer treatment. 
 
 Loading of polymeric NCs of photosensitizer into T lymphocytes by electroporation 
is a shift in paradigm of designing a photo-immune cell based delivery system 
which combines the advantages of phototherapy and immunotherapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
I. REFERENCES 
Abastado, J-P et al, World cancer report 2014. 2014, International Agency for 
Research on Cancer. Lyon, France. 1-630 
Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and 
photodynamic therapy. Photochem. Photobiol. 2001, 74: 656–69 
Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, 
Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, 
Wilson BC, Golab J. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 
2011, 61:250-81 
Ananya M. (http://www.news-medical.net/health/What-are-Cytokines.aspx) 
Anderson, B et al. Global cancer facts and figure, 3rd Edition. 2014. American Cancer 
Society. 1-61 
Arber W, Henle W, Hofschneider PH, Humphrey JH, Klein J, Koldovský P, Koprowski 
H, Maaløe O, Melchers F, Rott R, Schweiger HG, Syruček L. In Vitro and in Vivo 
Investigations on Antibody-Dependent Cellular Cytotoxicity. Current topics in 
microbiology and immunology. 1978, 80: 65-96 
Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of 
RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum 
Gene Ther. 2013, 24: 717-27 
Bastien E, Schneider R, Hackbarth S, Dumas D, Jasniewski J, Röder B, Lina 
Bezdetnaya L, Lassalle H-P. PAMAM G4.5-chlorin e6 dendrimeric nanoparticles for 
enhanced photodynamic effects.  Photochem Photobiol Sci.  2015,14: 2203-12 
Batist G, Gelmon KA, Chi KN, Miller WH Jr., Chia SK, et al. Safety, pharmacokinetics, 
and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin 
Cancer Res. 2009, 15: 692-700 
Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab 
Sci. 2009, 46: 167-89 
Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M. 
Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends 
Biotechnol. 2008, 26: 612-21 
 
Berman B, Amini S, Valins W, Block S. Pharmacotherapy of actinic keratosis. Expert 
Opin Pharmacother. 2009, 10: 3015-31  
 
Bharali D, Sahoo SK, Mozumdar A, Maitra A. Cross-linked polyvinylpyrrolidone 
nanoparticles: a potential carrier for hydrophilic drugs. J Colloid Interface Sci. 2003, 
15: 415-23. 
 
Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for 
cancer therapy. Exp Biol Med. 2009, 234: 123-31 
 
90 
 
Blaudszun AR, Moldenhauer G, Schneider M, Philippi A. A photosensitizer delivered 
by bispecific antibody redirected T lymphocytes enhances cytotoxicity against 
EpCAM-expressing carcinoma cells upon light irradiation. J Control Release. 2015, 
197: 58-68 
 
Boyer JC, Vetrone F, Cuccia LA, Capobianco JA. Synthesis of colloidal upconverting 
NaYF4 nanocrystals doped with Er3+, Yb3+ and Tm3+, Yb3+ via thermal 
decomposition of lanthanide trifluoroacetate precursors. J Am  Chem  Soc. 2006, 126: 
7444–45 
 
Bonnett R, Photosensitizers of the porphyrin and phthalocyanine series for 
photodynamic therapy, Chem Soc Rev. 1995, 24: 19–33. 
 
Brown SB, Brown EZ, Walker I. The present and future role of photodynamic therapy 
in cancer treatment. Lancet Oncol. 2004, 5: 497-08 
 
Byrne KT, Côté AL, Zhang P, Steinberg SM, Guo Y, Allie R, Zhang W, Ernstoff 
MS, Usherwood EJ, Turk MJ. Autoimmune melanocyte destruction is required for 
robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest. 2011, 121: 
1797-809 
 
Castano AP, Demidova TN, Hamblin MR. Mechanism in photodynamic therapy: part 
three- photosensitizer pharmacokinetics, biodistribution, tumor localization and modes 
of tumor destruction. Photodiagnosis Photodyn Ther. 2005, 2: 91-106 
 
Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an 
emerging paradigm. Adv Drug Deliv Rev. 2008, 60:1627-37 
Chen W, Zhang J. Using nanoparticles to enable simultaneous radiation and 
photodynamic therapies for cancer treatment. J Nanosci Nanotechnology. 2006, 6: 
1159–66 
 
Chen Y, Zheng X-L, Fang D-L, Yang Y, Zhang J-K, Li H-L, Xu B , Lei Y, Ren K, Song 
X-R. Dual Agent Loaded PLGA Nanoparticles Enhanced Antitumor Activity in a 
Multidrug-Resistant Breast Tumoreenograft Model. Int J Mol Sci. 2014,15: 2761-72 
Cho K, Wang Xu, Nie S, Chen Z, Shin DM. Therapeutic Nanoparticles for Drug 
Delivery in Cancer. Clin Cancer Res. 2008, 14: 1310 
 
Choudhary S, Nouri K, Elsaie ML. Photodynamic therapy in dermatology: A review. 
Lasers Med Sci. 2009, 24: 971-80 
 
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 
2013, 342: 1432–1433 
Chung JE, Tan S, Gao SJ, Yongvongsoontorn N, Kim SH, Lee JH, Choi HS. Yano H, 
Zhuo L, Kurisawa M, Ying JY. Self-assembled micellar nanocomplexes comprising 
green tea catechin derivatives and protein drug for cancer therapy. Nat Nanotechnol. 
2014, 11: 907-12 
91 
 
Daniell MD, Hill JS. A history of photodynamic therapy. Aust NZJ Surg. 1991, 61: 340–
48 
 
Dardel F, Arden TV. Ion Exchangers. Ullmann's Encyclopedia of Industrial Chemistry, 
2008, Wiley-VCH, Weinheim.  
Diamond I, McDonagh AF, Wilson CB, Granelli SI, Nielsen S, Jaenicke R. 
Photodynamic therapy of malignant tumours. Lancet. 1972, ii: 1175-77 
Di Corato R, Béalle G, Kolosnjaj-Tabi J, Espinosa A, Clément O, Silva AK, Ménager 
C, Wilhelm C. Combining magnetic hyperthermia and photodynamic therapy for tumor 
ablation with photoresponsive magnetic liposomes. ACS Nano. 2015, 24: 2904-16 
 
Dolmans DEJGJ, Fukumara D, Jain RK. Photodynamic therapy for cancer. Nat Rev 
Cancer. 2003, 3: 380-87 
 
Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med 
Surg. 2002, 20: 3-7 
 
Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DGJ. Photoradiation therapy 
II. Cure of animal tumors with hematoporphyrin and light. 1975. Natl. Cancer Inst. 55: 
115-21 
  
Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. 
Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978, 38: 
2628–35 
 
Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 
2004, 4: 11-22 
 
Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003, 5: 
347-60 
Ericson MB, Sandberg C, Stenquist B, et al. Photodynamic therapy of actinic keratosis 
at varying fl uence rates: assessment of photobleaching, pain and primary clinical 
outcome. Br J Dermatol. 2004, 151: 1204–12 
Ferreira DM, Saga YY, Aluicio-Sarduy E, Tedesco AC. Chitosan nanoparticles for 
melanoma cancer treatment by Photodynamic Therapy and electrochemotherapy 
using aminolevulinic acid derivatives. Curr  Med Chem. 2013, 20:1904-11 
Figge FHJ, Weiland GS, and Manganiello OJ. Cancer detection and therapy. Affinity 
of neoplastic, embryonic, and traumatized tissues for porphyrins and 
metalloporphyrins, Proc Soc Exp Biol Med. 1948, 68: 640–41 
Fisher, GH. et al. Induction and apoptotic regression of lung adenocarcinomas 
byregulation of a K-Rastransgene in the presence and absence of tumorsuppressor 
genes. Genes Dev. 2001, 15: 3249–62 
 
92 
 
Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical 
nanoparticles. Int J Nanomedicine. 2012, 7: 5577–91 
 
Fry TJ, Mackall CL. Interleukin 7: master regulator of peripheral T cell homeostasis? 
Trends Immunol. 2001, 22:564-71 
Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for 
the magic bullet. Clin Cancer Res. 2001, 7: 223-5 
Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, et al. Development of a novel 
systemic gene delivery system for cancer therapy with a tumor-specific cleavable 
PEG-lipid. Gene Ther. 2007, 14: 68-77 
 
Heer S, Kompe K, Gudel HU, Haase M. Highly efficient multicolour upconversion 
emission in transparent colloids of lanthanide-doped NaYF4 nanocrystals. Adv Mater. 
2004, 16: 2102–05 
 
Hopper C, Niziol C, Sidhu M. The cost effectiveness of Foscan mediated 
photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and 
palliative chemotherapy for patients with advanced head and neck cancer in the UK. 
Oral Oncol. 2004, 40: 372-82 
 
Hur C, Nishioka NS, Gazelle GS. Cost effectivenenss of photodynamic therapy for 
treatment of Barrett’s esophagus with high grade dysplasia. Dig Dis Sci. 2003, 48: 
1273-83 
 
Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi 
C, Minucci S, Pelicci PG. Inhibitors of histone deacetylases induce tumor-selective 
apoptosis through activation of the death receptor pathway. Nat Med. 2005, 11: 71–76 
 
Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles for oral 
delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to 
Sandimmune Neoral. J Control Release. 2007, 119:197-206 
Italia JL, Yahya MM, Ravi Kumar MNV. Biodegradable Nanoparticles Improve Oral 
Bioavailability of Amphotericin B and Show Reduced Nephrotoxicity Compared to 
Intravenous Fungizone®. Pharm Res. 2009, 6:1324-31 
 
Jain M et al. Sustained loss of neoplastic phenotype by brief inactivation of MYC. 
Science. 2002, 297:102-04 
 
Johnson LA et al. Gene therapy with human and mouse T-cell receptors mediates 
cancer regression and targets normal tissues expressing cognate antigen. Blood. 
2009, 114:535-45  
 
Josefsen LB, Boyle RW. Photodynamic therapy and the development of metal-based 
photosensitisers. Met Based Drugs. 2008, 2008: 276109 
 
93 
 
Juzeniene A, Peng Q, Mohan J. Milestones in the development of photodynamic 
therapy and fluorescence diagnosis. Photochem Photobiol Sci. 2007, 6:1234-45 
Katz P, Fauci AS. Antibody dependent cellular toxicity mediated by subpopulation of 
human T lymphocytes; killing of human erythrocytes and autologous lymphoid cells. 
Immunology. 1980, 39: 407-016 
 
Khan DR. The Use of Nanocarriers for Drug Delivery in Cancer Therapy. J Cancer Sci 
Ther. 2010, 2: 058-062 
 
Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, ZarourHM, Butterfield LH, Gogas 
HJ. Next generation of immunotherapyfor melanoma. J ClinOncol. 2008, 26: 3445–55 
 
Konan YN, Berton M, Gurny R, Allemann E. Enhanced photodynamic activity of meso-
tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J 
Pharm Sci. 2003a, 18: 241–49 
 
Konan-Kouakou YN, Boch R, Gurny R, Allemann E. In vitro and in vivo activities of 
verteporfin-loaded nanoparticles. J Control Release. 2005, 103: 83-91 
 
Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for 
photodynamic therapy. J Photochem Photobiol B. 2002, 66: 89-106 
Konan YN, Gerny R, Favet J, Berton M, Gurny R, Allemann E. Preparation and 
characterization of sterile sub-200 nmmeso-tetra(4-hydroxylphenyl)porphyrin-loaded 
nanoparticles for photodynamic therapy. Eur J Pharm Biopharm. 2003b, 55: 115–24 
 
Kourie JI. Interaction of reactive oxygen species with ion transport mechanisms. Am J 
Physiol. 1998, 275: C1-24 
 
Kraut EH, Fishman MN, Lorusso PM, Gordon MS, Rubin EH, et al. Final results of a 
phase I study of liposome encapsulated SN-38 (LESN38): Safety, 
pharmacogenomics, pharmacokinetics, and tumor response. Journal of Clinical 
Oncology-ASCO Annual Meeting Proceedings 23, 2005 
Kübler AC. Photodynamic therapy. Med Laser Appl. 2005, 20: 37-45 
 
Landazurimo-De MO, Silva A, Alvares J, Herberman RB. Evidence that natural 
cytotoxicity and antibody-dependent cellular cytotoxicity are mediated in humans by 
the same effector cell populations. J Immunol. 1979, 123: 252-58 
 
Lipson RL, Baldes EJ Olsen AM. The use of a derivative of hematoporhyrin in tumor 
detection, J Natl Cancer Inst. 1961, 26: 1–11 
 
Liu J, Blake SJ, Smyth MJ, Teng MW. Improved mouse models to assess tumor 
immunity and irAEs after combination cancer immunotherapies. Clin Trans 
Immunology.  2014, 3: e22  
94 
 
Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with 
bevacizumab and vatalanib in the treatment of advanced colorectal cancer. 
Oncologist. 2007, 12: 443-50 
Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic therapy. Chem Rev. 
2015, 115: 1990-2042 
Lukšienė Z. Photodynamic therapy: mechanism of action and ways to improve the 
efficiency of treatment. Medicina. 2003, 39: 12 
 
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the 
EPR effect in macromolecular therapeutics: a review. J Control Release. 2000, 65: 
271-84 
Mahmoud G, Jedelská J, StrehlowB, Bakowsky U. Bipolar tetraether lipids derived 
from thermoacidophilic archaeonSulfolobusacidocaldarius for membrane stabilization 
of chlorin e6 basedliposomes for photodynamic therapy. Eur J Pharm Biopharm. 2015, 
95: 88-98 
 
Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, 
Johnson TS, Storn V, Schallenberg S, Enk AH. Depletion of CD4+CD25+ human 
regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune 
functions in vivo and in vitro. Int J Cancer.  2007, 120: 2723–33 
 
Matsumura Y, Maeda HA. New concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor 
agent smancs. Cancer Res. 1986, 46: 6387-92 
 
McCarthy JR, Perez JM, Bruckner C, Weissleder R. Polymeric nanoparticle 
preparation that eradicates tumors. Nano Lett. 2005, 5: 2552–56 
McKeage K, Perry CM, Trastuzumab: a review of its use in the treatment of metastatic 
breast cancer overexpressing HER2. Drugs. 2002, 62: 209-43 
 
Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L, 
Immunostimulatorymonocolonal antibodies for cancer therapy. Nat Rev Cancer. 2007, 
7: 95-106 
 
Meyer-Betz F. Untersuchung uber die biologische (photodynamische) Wirkung des 
Hamatoporphyrins und anderer Derivate des Blutund Gallenfarbstoffs. Dtsch Arch Klin 
Med. 1913, 112: 476–503 
 
Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, Eidelstein Y, Afik R, 
Antebi YE, Dustin ML, Reisner Y. CTLs respond with activation and granule secretion 
when serving as targets for T-cell recognition. Blood. 2011, 117: 1042–52 
 
Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared 
Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the 
Effect of Immunoconjugate. Bioconjugate Chem. 2012, 23: 604–09 
 
95 
 
Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer 
cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane 
molecules. Nat Med. 2011, 17: 1685–91 
 
Monfrecola G, Fabbrocini G, Pinton PC. Photodynamic therapy for non-melanoma 
skin cancers. Curr Cancer Ther Rev. 2009, 5: 271-80 
 
Morgana NY, Kramer-Marekb G, Smitha PD, Camphausenb K, Capalab J. 
Nanoscintillator Conjugates as Photodynamic Therapy-Based Radiosensitizers: 
Calculation of Required Physical Parameters. Radiat Res. 2009, 17: 236–44 
 
Motiff  EA. Blood substitutes. Can Anaesth Soc J. 1975, 22:12-9 
 
Mroz P. Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell Death Pathways in 
Photodynamic Therapy of Cancer. Cancers. 2011, 3: 2516-39 
 
Myers JN, Rekhadevi PV, Ramesh A. Comparative evaluation of different cell lysis 
and extraction methods for studying benzo(a)pyrene metabolism in HT-29 colon 
cancer cell cultures. Cell Physiol Biochem. 2011, 28: 209-18 
 
Nayak CS. Photodynamic therapy in dermatology. Indian J Dermatol Venerol Leprol. 
2005, 71: 155-60 
 
Nazaran MH et al. BCc1, the novel antineoplastic nanocomplex, showed potent 
anticancer effects in vitro and in vivo. Drug Des Devel Ther. 2015, 10: 59–70 
 
Nazaran MH et al. The therapeutic effects of MSc1 nanocomplex, synthesized by 
nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 
mice. Int J Nanomed. 2014, 9: 3841-53 
 
Ochsner M. Photophysical and photobiological processes in the photodynamic therapy 
of tumours. J Photochem Photobiol B. 1997, 39: 1-18 
 
Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, Kurihara 
C, Kawaguchi A, Nagao S, Azuma M, Yagita H, Miura. Blockade of B7-H1 or B7-DC 
induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol. 2009, 
35: 741-9 
 
Oleinik NL, Evans HH. The photobiology of photodynamic therapy: Cellular targets 
and mechanisms. Radiation Res. 1998, 150:146-56 
 
Park S. Delivery of photosensitizers for photodynamic therapy. Korean J 
Gastroenterol. 2007, 49: 300-13 
Pass HI. Photodynamic therapy in oncology: Mechanisms and clinical use. J Natl 
Cancer Inst. 1993, 85: 443-56 
96 
 
Persson J, Beyer I, Yumul R, Li Z, Kiem H-P, et al. Immuno-Therapy with Anti- TLA4 
Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models. PLoS ONE. 2011, 
6(7): e22303 
 
Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: 
correlations with PEG molecular weight. J Control Release. 2003, 90: 323-34 
 
Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic 
acid topical solution and visible blue, light in the treatment of multiple actinic keratoses 
of the face and scalp – investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 
2004, 140: 41–6 
 
Pichierri, F. Dipole-dipole interactions in protein-protein complexes: a quantum 
mechanical study of the ubiquitin-Dsk2 complex. QPI. 2013, 1:1-8 
 
Pirollo KF, Nemunaitis, Leung PK, Nunan RJ, Adams J, Chang EH. Safety and 
Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 
Gene Used in Combination with Docetaxel: A Phase 1b Study Mol Ther. 2016, Aug 2. 
doi: 10.1038/mt.2016.135. [Epub ahead of print] 
 
Plaetzer K, Kiesslich T, Verwanger T, Krammer B. The modes of cell death induced by 
PDT: An overview.  Med Laser Appl. 2003, 18: 7-19 
 
Poirier A, et al. Design, data analysis and simulation of in vitro drug transport kinetic 
experiments using a mechanistic in vitro model. Drug Metab. Dispos. 2008, 36: 2434–
44 
 
Powell E, Lee Y-H, Partch R,  Dennis D,  Morey T,  Varshney M, Pi-Pi complexation of 
bupivacaine and analogues with aromatic receptors: Implications for overdose 
remediation. Int J Nanomedicine. 2007, 2: 449–59 
 
Prime S, Littlewood T,  Khan M, Elia G, Evan GI. Supression of Myc-induced 
apoptosis in beta cellsexposes multiple oncogenic properties of Myc and triggers 
carcinogenic progression. Mol Cell.  1900, 3: 565-77 
 
Raab O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Zeitung Biol. 1900, 
39: 524–26 
 
Reum N, Fink-Straube C, Klein T, hartmann RW, Lehr C-M, Schneider M. Multilayer 
Coating of Gold Nanoparticles with Drug-Polymer Coadsorbates. Langmuir. 2010, 26: 
16901–08 
 
Reum N, Schneider M. Multilayer coating of gold nanoparticles (AuNP) with drug-
polymer complex: Development and characterization. Thesis. 2011, 1–129 
 
Rothschild WG: Binding of hydrogen donors by peptide groups of lactams. Identity of 
the reaction sites. J Am Chem Soc.1972, 94: 8676–83  
 
Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, Dougherty 
TJ, Prasad PN. Ceramic-based nanoparticles entrapping water-insoluble 
97 
 
photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic 
therapy. J Am Chem Soc. 2003, 125: 7860–65 
 
Rubinsky B. Irreversible electroporation in medicine. Technol. Cancer Res Treat. 
2007, 6: 255-60 
 
Ruifrok PG, Meijer DK. Transport of organic ions through lipid bilayers. Naunyn 
Schmiedebergs  Arch Pharmacol. 1981, 316: 266–72 
  
Sandberg C, Stenquist B, Rosdahl I, et al. Important factors for pain during 
photodynamic therapy for actinic keratosis. Acta DermatoVenereologica. 2006, 86: 
404–8 
 
Santos-Carballal B, Aaldering LJ, Ritzefeld M, Pereira S, Sewald N, Moerschbacher 
BM, Götte M, Goycoolea FM. Physicochemical and biological characterization of 
chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. 
Sci Rep. 2015, 5: 1-14 
 
Saroj AL, Singh RK, Chandra S. Studies on polymer electrolyte poly(vinyl)pyrrolidone 
(PVP) complexed with ionic liquid: Effect of complexation on thermal stability, 
conductivity and relaxationbehavior. Material Science and Enginnering B. 2013, 178: 
231–38 
 
Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative 
"null" and "T" cell lines derived from children with acute lymphoblastic leukemia and 
leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977, 19: 621-6 
 
Schreck S, Pietzsch A, Kennedy B, Såthe C, . Miedema PS, Techert A, Strocov VN, 
Schmitt T, Hennies F, Rubensson E, Föhlisch A. Ground state potential energy 
surfaces around selected atoms from resonant inelastic x-ray scattering. Sci 
Rep. 2016, 20054: 1-7 
 
Sharma D, Chelvi TP, Kaur J, Chakravorty K, De TK, Maitra A, Ralhan R. Novel Taxol 
formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in 
cancer therapy. Oncol Res. 1996, 8: 281-06 
 
Shi C, Khan SA, Wand K, Schneider M. Improved delivery of the natural anticancer 
drug tetrandrine. Int J Pharm. 2015, 479: 41-51 
 
Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid 
malignancies. Clin Ther. 2006, 28:1779-802 
 
Sikora, J.; Orlov, S. N.; Furuya, K.; Grygorczyk, R. Hemolysis is a primary ATP-
release mechanism in human erythrocytes, Blood. 2014, 124: 2150–57 
 
Smits T, Moor ACE. New aspects in photodynamic therapy of actinic keratoses. J 
Photochem Photobiol B: Biology. 2009, 96: 159-69 
 
Songca SP, Oluwafeml OS. Photodynamic therapy: A new light for the developing 
world. Afr J Biotechnol. 2013, 12: 3590-99 
98 
 
 
Sugano K, Kansi M, Artursson P, Avdeef A, Bendles S, Di L, Ecker GF, Faller B, 
Fischer H, Gerebtzoff G, Lennernaes S, Senner F. Coexistence of passive and carrier 
mediated processes in drug transport. Nat Rev Drug Discov. 2010, 9: 597-614 
 
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, 
Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T 
lymphocyteassociated antigen 4 blockade and depletion of CD25(+) regulatoryT cells 
in antitumor therapy reveals  alternative pathwaysfor suppression of autoreactive 
cytotoxic T lymphocyteresponses. J Exp Med. 2001, 194: 823–32 
 
Tersigni SH. Core-excited nanoparticles and methods of their use in the diagnosis and 
treatment of disease. United State Patent. 2012, Patent no. US8,197,471,B1 
 
Thakor A, Gambhir S. Nanooncology: The future of cancer diagnosis and therapy. Ca 
Cancer J Clin. 2013, 63: 395-418 
 
Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. 
AAPS. 2007, J9: E128-47 
 
Tschen EH, Wong DS, Pariser DM, et al: Photodynamic therapy using aminolaevulinic 
acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: Phase 
IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006, 155:1262-
1269 
 
Vivek R, Nipun Babu V, Thangam R, Subramanian KS, Kannan S. pH-
responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective 
anti-tumor activity inbreast cancer cells. Colloids Surf B Biointerfaces. 2013, 111: 117-
23 
 
von Specht BU, Seinfeld H, Brendel W. Polyvinylpyrrolidone as a soluble carrier of 
proteins. Hoppe Seylers Z Physiol Chem. 1973, 354: 1659-60 
 
Wang X, Yang L, Chen ZG, and Shin DM. Application of nanotechnology in cancer 
therapy and imaging. CA Cancer J Clin. 2008, 58: 97-110 
 
Wang Y, Lin Y, Zhang H-g, Zhu J. A photodynamic therapy combined with topical 
5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but 
less phototoxic for cancer. J Cancer Res Clin Oncol. 2016, 142: 813–821 
 
Weissleder R, Ntziachristos V. Shedding light onto live molecular target. Nat Med. 
2003, 1: 123-8 
 
Wieder ME, Hone DC, Cook MJ, Handsley MM, Gavrilovic J, Russell DA. Intracellular 
photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy 
using a ‘Trojan horse’. Photochem  Photobiol Sci. 2006,  5: 727–34 
 
Wijnja H, Pignatello JJ, Malekani K. Formation of pi-pi complexes between 
phenanthrene and model pi-acceptor humic subunits. J Environ Qual. 2004, 33: 265-
75 
99 
 
 
Wohrle D, Hirth A, Bogdahn-Rai T, Schnurpfeil G, Shopova M. Photodynamic therapy 
of cancer: second and third generations of photosensitizers. Russ Chem Bull. 1998, 
47: 807–16 
 
Wu H, Zhu L, Torchilin VP. pH-sensitive-(hisitidine)-PEG/DSPE-PEG co-polymer 
micelles for cytosolic drug delivery. Biomaterials. 2013, 34: 1213-22 
 
Wu ZM, Ling L, Zhou LY,Guo XD, Jiang W, Qian Y,Luo KQ, Zhang LJ. Novel 
preparation of PLGA/HP55 nanoparticles for oral insulin delivery. Nanoscale Res Lett. 
2012, 7: 299 
 
Yang T, Cui F-D, Choi M-K, Cho J-W, Chung S-J, Shim C-K, Kim D-D. Enhanced 
solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. 
Int J Pharm. 2007, 338: 317-26 
 
Zeisser-Labouebe M, Lange N, Gurny R, Delie F. Hypericin-loaded nanoparticles for 
the photodynamic treatment of ovarian cancer. Int J Pharm. 2006, 326:174–81 
 
Zhao N, Bagaria HG, Wong MS,  Zu Y. A nanocomplex that is both tumor cell-
selective and cancer gene-specific for anaplastic large cell lymphoma. J 
Nanobiotechnology. 2011, 9: 1-12 
 
Zijlmans HJ, Bonnet J, Burton J, Kardos K, Vail T, Niedbala RS, Tanke HJ. Detection 
of cell and tissue surface antigens using up-converting phosphors: a new reporter 
technology. Anal Biochem. 1999, 267: 30–36 
 
 
Website References 
http://goldbook.iupac.org/P04652.html 
http://www.sciencemag.org/news/2013/12/sciences-top-10-breakthroughs-2013 
 
Hum Gene Ther. 2013 Aug;24(8):717-27. doi: 10.1089/hum.2013.075. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
 
J. ERKLÄRUNG 
 
 
 
 
 
Ich versichere, dass ich meine Dissertation  
 
 
selbständig ohne unerlaubte Hilfe angefertigt und mich dabei keiner anderen als der 
von mir ausdrücklich bezeichneten Quellen bedient habe. Alle vollständig oder 
sinngemäß übernommenen sind Zitate als solche gekennzeichnet. 
 
Die Dissertation wurde in der jetzigen oder einer ähnlichen Form noch bei keiner 
anderen Hochschule eingereicht und hat noch keinen sonstigen Prüfungszwecken 
gedient. 
 
 
Marburg, den 03/11/2016 
 
 
Mohammad Yahya Momin 
....................................................... 
(Unterschrift mit Vor- und Zuname) 
 
 
 
101 
 
K. CURRICULUM VITAE 
Name: Mohammad-Yahya Momin 
Qualification: PhD (Pharmaceutics and Biopharmaceutics) 
Pharmacist, M.S. (Pharmaceutics), B. Pharm.   
Nationality: Indian  
Gender: Male 
Languages:  English: Fluent; German: Middle level (B1) 
Urdu and Hindi: Native speaker  
E-mail id: mominzy@gmail.com 
 
 
PhD in Pharmaceutics and Biopharmaceutics (September 2014- December 2016) 
Faculty of Pharmacy, Department of Pharmaceutics and Biopharmaceutics) 
Philipps University of Marburg, Germany 
 
Title of thesis: “An injectable formulation of polymeric photosensitizer nanocomplex-
encapsulated T lymphocytes in photodynamic therapy of cancer” 
 
 Synthesis and characterization of  polymeric nanoparticles for drug delivery 
application (polymeric, solid lipid nanoparticle, polymeric nanocomplexes, 
liposomes) 
 Internalization of polymeric nanoparticles into T cells (immune cell based delivery 
system) 
 Electroporation 
 Release studies with Franz diffusion cell 
 Measurement of particles size, PDI and zeta potential by dynamic light scattering 
 Analytical method development, validation, quantification by UV- and fluorescence 
spectroscopies  
 Atomic force microscopy  and Confocal laser scanning microscopy 
 Cellular studies (cytotoxicity, anticancer, haemotoxicity studies) 
 Photodynamic therapy 
 Synthesis and characterization of  solid lipid nanoparticles for drug delivery 
application 
 Internalization of polymeric nanoparticles into T cells (immune cell based delivery 
system) 
 
PhD Research Scholar (November 2011- April 2013) 
Institute of Pharmacy, Department of Pharmacology and Toxicology, Free 
University of Berlin, Germany 
 
 
Lecturer in Pharmaceutics (January 2009 – May 2011) 
Dr.  BN College of Pharmacy (Mumbai University, India) 
 
 Lectures, conducting practical of Pharmaceutical Technology and supervision of 
undergraduates 
 Mentorship  
Academic and professional experience 
102 
 
  
Research Associate Formulation R & D (3 months) 
In 2008, Ajanta Pharma Pvt. Ltd., Mumbai, India 
 
 Optimization of pharmaceutical process for development of conventional dosage 
forms system  
 
Master of Science   
July 2005 – December 2007 in Department of Pharmaceutics, National Institute of 
Pharmaceutical Education and Research (NIPER)-Mohali, India  
 
Title of thesis: “Nanoparticulate Formulation of Amphotericin B for Oral Delivery” 
 
 Development and characterization of nanoparticles  
 HPLC-in vitro and in vivo analytical method development and validation as per ICH 
guideline 
 Enhancing poor bioavailability and aqueous solubility of challenging and difficult-to-
deliver drug molecules  
 Photon-imager for live tracking of fluorescent nanoparticles in animal (exposure) 
 IPR (Intellectual Property Right)-searching patent data base and commercialization 
of patentable  formulations 
 
 
Bachelor in Pharmacy  
August 2001 - May 2005 from Bombay College of Pharmacy (Mumbai University), 
India 
 
 All theories and practicals of pharmaceutical sciences 
 Industrial training in manufacturing, research and development and quality control 
of solid and liquid oral delivery systems 
 
GATE/Graduate Aptitude Test in Engineering (Pharmacy)  
In March 2005 conducted by IIT (Indian Institute of Technology), Bombay, India  
(GATE is a national level entrance exam for postgraduate studies) 
 
 
NIPER national level entrance test (Pharmacy)  
In May 2005 conducted by NIPER-Mohali  
(GATE is a national level entrance exam for postgraduate studies) 
 
Diploma in Pharmacy   
August 1999 - May 2001, Mumbai University, India 
 
 
Publications 
     
 Mohammad-Yahya Momin, Shashank Reddy, Udo Bakowsky, Marc Schneider. 
Polymeric nanocomplex of porphyrine photosensitizer-loading into T lymphocyte for 
photo-immunotherapy of cancer. Manuscript under publication process 
Publications and presentations 
103 
 
 Mohammad-Yahya Momin, Pramod Nair, Udo Bakowsky, Marc Schneider. 
Complexation potential of water soluble polymers with porphyrine for drug delivery: 
A comparative investigation based on UV spectroscopy and computational 
modelling. Manuscript under writing. 
 
 Küchler S, Wolf NB, Heilmann S, Weindl G, Helfmann J, Yahya MM, Stein 
C, Schäfer-Korting M. 3D-Wound healing model: Influence of morphine and solid 
lipid nanoparticles. Journal of Biotechnology 148(2010), 24–30 (Impact factor; 3.18)  
 
 Italia JL, Yahya MM, Singh D, Ravi Kumar MN. Biodegradable Nanoparticles 
Improve Oral Bioavailability of amphotericin B and Show Reduced Nephrotoxicity 
Compared to Intravenous Fungizone®. Pharmaceutical Research 26(6):1324-31 
(Impact factor; 3.42) 
 
 
Presentations 
 
 Poster- MY Momin, Shashank P. Reddy, U. Bakowsky, M. Schneider. Polymeric 
nanocomplexes of photosensitizers loaded T lymphocytes for photodynamic 
therapy of cancer. NANO-SMAT 2016 May 18-20, 2016 in University of Texas, 
Arlington-USA  
(Best scientific poster presentation award) 
 
 Oral- MY Momin, Shashank P. Reddy, U. Bakowsky, M. Schneider. Polymeric 
nanocomplexes of photosensitizers loaded T lymphocytes for photodynamic 
therapy of cancer. NANO-SMAT 2016 May 18-20, 2016 in University of Texas, 
Arlington-USA  
 
 
 Poster- MY Momin, JL Italia, MNV Ravi Kumar. Development  and  in  vivo  
evaluation  of  nanoparticulate  formulation  of  Amphotericin  B”  at 35thAnnual 
Meeting Exposition of Controlled Release, July 12-16, 2008 in New York-USA  
 
 
 
 
Scholarship 
 Travel award by DAAD to attend NANOSMAT 2016 international conference, 
Texas, USA (2016)   
 Philipps University of Marburg Scholarship for PhD  
 Government of India national scholarship for M.S. (Pharmaceutics) (2005-2007) 
 MESCO-Scholarship for Bachelor in Pharmacy und Diploma in Pharmacy(2001-
2005)  
 
Achievements 
 Best poster award at University of Texas for PhD research work (2016) 
 First prize as Human Relationship Award in UXL Training during M.S. in 
Pharmaceutics (2007)   
Awards and Achievements 
104 
 
 First prize for speech as “HIV AIDS Literate” in Diploma in Pharmacy (1999)  
 First prize in essay writing competition in Urdu from Rotary Club Mumbai, India 
(1994)   
 "Excellence in B. Pharmacy Award“ from MESCO (2005)  
 
 
     
 
 
 
 
   Prof. Dr. M. Schneider  
Head of the Department 
(Former Professor at Philipps Universität Marburg) 
Biopahrmaceutics and Pharmaceutical Technology 
University of Saarland 
Campus A41 D-66123 Saarbruecken, Deutschland 
Tel: +49/68130-22438 
E-mail: marc.schneider@mx.uni-saarland.de 
 
 Prof. Dr. U. Bakowsky 
Head of the Department 
Pharmaceutics and Biopharmaceutics 
Philipps University of Marburg 
35039-Marburg, Deutschland 
Tel: +49/642128-25884 (Mo-Do) 
E-mail: ubakowsky@aol.com 
 
 
 
Computer proficiency 
Referees 
   MS Office 
(advanced) 
    In-design 
 Scientific and 
   End note 
 Scientific and 
